


<!DOCTYPE html>
<html lang="en-CA">
  <head>
    <title>
    Type 2 diabetes: insulin therapy |     Centre for Effective Practice - Digital Tools        </title>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width" />
  <meta name="theme-color" content="#999999" />
  <link href="https://fonts.googleapis.com/css?family=Montserrat:500,500i,700,700i|Open+Sans:400,400i,700,700i&display=swap" rel="stylesheet">
  <meta name='robots' content='noindex, nofollow' />
	<style>img:is([sizes="auto" i], [sizes^="auto," i]) { contain-intrinsic-size: 3000px 1500px }</style>
	<link rel='dns-prefetch' href='//a.omappapi.com' />
<link rel='dns-prefetch' href='//www.googletagmanager.com' />
		<!-- This site uses the Google Analytics by MonsterInsights plugin v9.5.3 - Using Analytics tracking - https://www.monsterinsights.com/ -->
							<script src="//www.googletagmanager.com/gtag/js?id=G-G1F4BDXK7E"  data-cfasync="false" data-wpfc-render="false" type="text/javascript" async></script>
			<script data-cfasync="false" data-wpfc-render="false" type="text/javascript">
				var mi_version = '9.5.3';
				var mi_track_user = true;
				var mi_no_track_reason = '';
								var MonsterInsightsDefaultLocations = {"page_location":"https:\/\/tools.cep.health\/tool\/type-2-diabetes-insulin-therapy\/"};
				if ( typeof MonsterInsightsPrivacyGuardFilter === 'function' ) {
					var MonsterInsightsLocations = (typeof MonsterInsightsExcludeQuery === 'object') ? MonsterInsightsPrivacyGuardFilter( MonsterInsightsExcludeQuery ) : MonsterInsightsPrivacyGuardFilter( MonsterInsightsDefaultLocations );
				} else {
					var MonsterInsightsLocations = (typeof MonsterInsightsExcludeQuery === 'object') ? MonsterInsightsExcludeQuery : MonsterInsightsDefaultLocations;
				}

								var disableStrs = [
										'ga-disable-G-G1F4BDXK7E',
									];

				/* Function to detect opted out users */
				function __gtagTrackerIsOptedOut() {
					for (var index = 0; index < disableStrs.length; index++) {
						if (document.cookie.indexOf(disableStrs[index] + '=true') > -1) {
							return true;
						}
					}

					return false;
				}

				/* Disable tracking if the opt-out cookie exists. */
				if (__gtagTrackerIsOptedOut()) {
					for (var index = 0; index < disableStrs.length; index++) {
						window[disableStrs[index]] = true;
					}
				}

				/* Opt-out function */
				function __gtagTrackerOptout() {
					for (var index = 0; index < disableStrs.length; index++) {
						document.cookie = disableStrs[index] + '=true; expires=Thu, 31 Dec 2099 23:59:59 UTC; path=/';
						window[disableStrs[index]] = true;
					}
				}

				if ('undefined' === typeof gaOptout) {
					function gaOptout() {
						__gtagTrackerOptout();
					}
				}
								window.dataLayer = window.dataLayer || [];

				window.MonsterInsightsDualTracker = {
					helpers: {},
					trackers: {},
				};
				if (mi_track_user) {
					function __gtagDataLayer() {
						dataLayer.push(arguments);
					}

					function __gtagTracker(type, name, parameters) {
						if (!parameters) {
							parameters = {};
						}

						if (parameters.send_to) {
							__gtagDataLayer.apply(null, arguments);
							return;
						}

						if (type === 'event') {
														parameters.send_to = monsterinsights_frontend.v4_id;
							var hookName = name;
							if (typeof parameters['event_category'] !== 'undefined') {
								hookName = parameters['event_category'] + ':' + name;
							}

							if (typeof MonsterInsightsDualTracker.trackers[hookName] !== 'undefined') {
								MonsterInsightsDualTracker.trackers[hookName](parameters);
							} else {
								__gtagDataLayer('event', name, parameters);
							}
							
						} else {
							__gtagDataLayer.apply(null, arguments);
						}
					}

					__gtagTracker('js', new Date());
					__gtagTracker('set', {
						'developer_id.dZGIzZG': true,
											});
					if ( MonsterInsightsLocations.page_location ) {
						__gtagTracker('set', MonsterInsightsLocations);
					}
										__gtagTracker('config', 'G-G1F4BDXK7E', {"forceSSL":"true","link_attribution":"true","page_path":location.pathname + location.search + location.hash} );
															window.gtag = __gtagTracker;										(function () {
						/* https://developers.google.com/analytics/devguides/collection/analyticsjs/ */
						/* ga and __gaTracker compatibility shim. */
						var noopfn = function () {
							return null;
						};
						var newtracker = function () {
							return new Tracker();
						};
						var Tracker = function () {
							return null;
						};
						var p = Tracker.prototype;
						p.get = noopfn;
						p.set = noopfn;
						p.send = function () {
							var args = Array.prototype.slice.call(arguments);
							args.unshift('send');
							__gaTracker.apply(null, args);
						};
						var __gaTracker = function () {
							var len = arguments.length;
							if (len === 0) {
								return;
							}
							var f = arguments[len - 1];
							if (typeof f !== 'object' || f === null || typeof f.hitCallback !== 'function') {
								if ('send' === arguments[0]) {
									var hitConverted, hitObject = false, action;
									if ('event' === arguments[1]) {
										if ('undefined' !== typeof arguments[3]) {
											hitObject = {
												'eventAction': arguments[3],
												'eventCategory': arguments[2],
												'eventLabel': arguments[4],
												'value': arguments[5] ? arguments[5] : 1,
											}
										}
									}
									if ('pageview' === arguments[1]) {
										if ('undefined' !== typeof arguments[2]) {
											hitObject = {
												'eventAction': 'page_view',
												'page_path': arguments[2],
											}
										}
									}
									if (typeof arguments[2] === 'object') {
										hitObject = arguments[2];
									}
									if (typeof arguments[5] === 'object') {
										Object.assign(hitObject, arguments[5]);
									}
									if ('undefined' !== typeof arguments[1].hitType) {
										hitObject = arguments[1];
										if ('pageview' === hitObject.hitType) {
											hitObject.eventAction = 'page_view';
										}
									}
									if (hitObject) {
										action = 'timing' === arguments[1].hitType ? 'timing_complete' : hitObject.eventAction;
										hitConverted = mapArgs(hitObject);
										__gtagTracker('event', action, hitConverted);
									}
								}
								return;
							}

							function mapArgs(args) {
								var arg, hit = {};
								var gaMap = {
									'eventCategory': 'event_category',
									'eventAction': 'event_action',
									'eventLabel': 'event_label',
									'eventValue': 'event_value',
									'nonInteraction': 'non_interaction',
									'timingCategory': 'event_category',
									'timingVar': 'name',
									'timingValue': 'value',
									'timingLabel': 'event_label',
									'page': 'page_path',
									'location': 'page_location',
									'title': 'page_title',
									'referrer' : 'page_referrer',
								};
								for (arg in args) {
																		if (!(!args.hasOwnProperty(arg) || !gaMap.hasOwnProperty(arg))) {
										hit[gaMap[arg]] = args[arg];
									} else {
										hit[arg] = args[arg];
									}
								}
								return hit;
							}

							try {
								f.hitCallback();
							} catch (ex) {
							}
						};
						__gaTracker.create = newtracker;
						__gaTracker.getByName = newtracker;
						__gaTracker.getAll = function () {
							return [];
						};
						__gaTracker.remove = noopfn;
						__gaTracker.loaded = true;
						window['__gaTracker'] = __gaTracker;
					})();
									} else {
										console.log("");
					(function () {
						function __gtagTracker() {
							return null;
						}

						window['__gtagTracker'] = __gtagTracker;
						window['gtag'] = __gtagTracker;
					})();
									}
			</script>
				<!-- / Google Analytics by MonsterInsights -->
		<link rel='stylesheet' id='wp-block-library-css' href='https://tools.cep.health/wp-includes/css/dist/block-library/style.min.css?ver=6.8.2' media='all' />
<style id='classic-theme-styles-inline-css' type='text/css'>
/*! This file is auto-generated */
.wp-block-button__link{color:#fff;background-color:#32373c;border-radius:9999px;box-shadow:none;text-decoration:none;padding:calc(.667em + 2px) calc(1.333em + 2px);font-size:1.125em}.wp-block-file__button{background:#32373c;color:#fff;text-decoration:none}
</style>
<style id='global-styles-inline-css' type='text/css'>
:root{--wp--preset--aspect-ratio--square: 1;--wp--preset--aspect-ratio--4-3: 4/3;--wp--preset--aspect-ratio--3-4: 3/4;--wp--preset--aspect-ratio--3-2: 3/2;--wp--preset--aspect-ratio--2-3: 2/3;--wp--preset--aspect-ratio--16-9: 16/9;--wp--preset--aspect-ratio--9-16: 9/16;--wp--preset--color--black: #000000;--wp--preset--color--cyan-bluish-gray: #abb8c3;--wp--preset--color--white: #ffffff;--wp--preset--color--pale-pink: #f78da7;--wp--preset--color--vivid-red: #cf2e2e;--wp--preset--color--luminous-vivid-orange: #ff6900;--wp--preset--color--luminous-vivid-amber: #fcb900;--wp--preset--color--light-green-cyan: #7bdcb5;--wp--preset--color--vivid-green-cyan: #00d084;--wp--preset--color--pale-cyan-blue: #8ed1fc;--wp--preset--color--vivid-cyan-blue: #0693e3;--wp--preset--color--vivid-purple: #9b51e0;--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple: linear-gradient(135deg,rgba(6,147,227,1) 0%,rgb(155,81,224) 100%);--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan: linear-gradient(135deg,rgb(122,220,180) 0%,rgb(0,208,130) 100%);--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange: linear-gradient(135deg,rgba(252,185,0,1) 0%,rgba(255,105,0,1) 100%);--wp--preset--gradient--luminous-vivid-orange-to-vivid-red: linear-gradient(135deg,rgba(255,105,0,1) 0%,rgb(207,46,46) 100%);--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray: linear-gradient(135deg,rgb(238,238,238) 0%,rgb(169,184,195) 100%);--wp--preset--gradient--cool-to-warm-spectrum: linear-gradient(135deg,rgb(74,234,220) 0%,rgb(151,120,209) 20%,rgb(207,42,186) 40%,rgb(238,44,130) 60%,rgb(251,105,98) 80%,rgb(254,248,76) 100%);--wp--preset--gradient--blush-light-purple: linear-gradient(135deg,rgb(255,206,236) 0%,rgb(152,150,240) 100%);--wp--preset--gradient--blush-bordeaux: linear-gradient(135deg,rgb(254,205,165) 0%,rgb(254,45,45) 50%,rgb(107,0,62) 100%);--wp--preset--gradient--luminous-dusk: linear-gradient(135deg,rgb(255,203,112) 0%,rgb(199,81,192) 50%,rgb(65,88,208) 100%);--wp--preset--gradient--pale-ocean: linear-gradient(135deg,rgb(255,245,203) 0%,rgb(182,227,212) 50%,rgb(51,167,181) 100%);--wp--preset--gradient--electric-grass: linear-gradient(135deg,rgb(202,248,128) 0%,rgb(113,206,126) 100%);--wp--preset--gradient--midnight: linear-gradient(135deg,rgb(2,3,129) 0%,rgb(40,116,252) 100%);--wp--preset--font-size--small: 13px;--wp--preset--font-size--medium: 20px;--wp--preset--font-size--large: 36px;--wp--preset--font-size--x-large: 42px;--wp--preset--spacing--20: 0.44rem;--wp--preset--spacing--30: 0.67rem;--wp--preset--spacing--40: 1rem;--wp--preset--spacing--50: 1.5rem;--wp--preset--spacing--60: 2.25rem;--wp--preset--spacing--70: 3.38rem;--wp--preset--spacing--80: 5.06rem;--wp--preset--shadow--natural: 6px 6px 9px rgba(0, 0, 0, 0.2);--wp--preset--shadow--deep: 12px 12px 50px rgba(0, 0, 0, 0.4);--wp--preset--shadow--sharp: 6px 6px 0px rgba(0, 0, 0, 0.2);--wp--preset--shadow--outlined: 6px 6px 0px -3px rgba(255, 255, 255, 1), 6px 6px rgba(0, 0, 0, 1);--wp--preset--shadow--crisp: 6px 6px 0px rgba(0, 0, 0, 1);}:where(.is-layout-flex){gap: 0.5em;}:where(.is-layout-grid){gap: 0.5em;}body .is-layout-flex{display: flex;}.is-layout-flex{flex-wrap: wrap;align-items: center;}.is-layout-flex > :is(*, div){margin: 0;}body .is-layout-grid{display: grid;}.is-layout-grid > :is(*, div){margin: 0;}:where(.wp-block-columns.is-layout-flex){gap: 2em;}:where(.wp-block-columns.is-layout-grid){gap: 2em;}:where(.wp-block-post-template.is-layout-flex){gap: 1.25em;}:where(.wp-block-post-template.is-layout-grid){gap: 1.25em;}.has-black-color{color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-color{color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-color{color: var(--wp--preset--color--white) !important;}.has-pale-pink-color{color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-color{color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-color{color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-color{color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-color{color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-color{color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-color{color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-color{color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-color{color: var(--wp--preset--color--vivid-purple) !important;}.has-black-background-color{background-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-background-color{background-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-background-color{background-color: var(--wp--preset--color--white) !important;}.has-pale-pink-background-color{background-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-background-color{background-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-background-color{background-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-background-color{background-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-background-color{background-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-background-color{background-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-background-color{background-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-background-color{background-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-background-color{background-color: var(--wp--preset--color--vivid-purple) !important;}.has-black-border-color{border-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-border-color{border-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-border-color{border-color: var(--wp--preset--color--white) !important;}.has-pale-pink-border-color{border-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-border-color{border-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-border-color{border-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-border-color{border-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-border-color{border-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-border-color{border-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-border-color{border-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-border-color{border-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-border-color{border-color: var(--wp--preset--color--vivid-purple) !important;}.has-vivid-cyan-blue-to-vivid-purple-gradient-background{background: var(--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple) !important;}.has-light-green-cyan-to-vivid-green-cyan-gradient-background{background: var(--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan) !important;}.has-luminous-vivid-amber-to-luminous-vivid-orange-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange) !important;}.has-luminous-vivid-orange-to-vivid-red-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-orange-to-vivid-red) !important;}.has-very-light-gray-to-cyan-bluish-gray-gradient-background{background: var(--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray) !important;}.has-cool-to-warm-spectrum-gradient-background{background: var(--wp--preset--gradient--cool-to-warm-spectrum) !important;}.has-blush-light-purple-gradient-background{background: var(--wp--preset--gradient--blush-light-purple) !important;}.has-blush-bordeaux-gradient-background{background: var(--wp--preset--gradient--blush-bordeaux) !important;}.has-luminous-dusk-gradient-background{background: var(--wp--preset--gradient--luminous-dusk) !important;}.has-pale-ocean-gradient-background{background: var(--wp--preset--gradient--pale-ocean) !important;}.has-electric-grass-gradient-background{background: var(--wp--preset--gradient--electric-grass) !important;}.has-midnight-gradient-background{background: var(--wp--preset--gradient--midnight) !important;}.has-small-font-size{font-size: var(--wp--preset--font-size--small) !important;}.has-medium-font-size{font-size: var(--wp--preset--font-size--medium) !important;}.has-large-font-size{font-size: var(--wp--preset--font-size--large) !important;}.has-x-large-font-size{font-size: var(--wp--preset--font-size--x-large) !important;}
:where(.wp-block-post-template.is-layout-flex){gap: 1.25em;}:where(.wp-block-post-template.is-layout-grid){gap: 1.25em;}
:where(.wp-block-columns.is-layout-flex){gap: 2em;}:where(.wp-block-columns.is-layout-grid){gap: 2em;}
:root :where(.wp-block-pullquote){font-size: 1.5em;line-height: 1.6;}
</style>
<link rel='stylesheet' id='studio123_styles-css' href='https://tools.cep.health/wp-content/themes/cep-tools/style.min.css?ver=1743561782' media='all' />
<link rel='stylesheet' id='glossary-hint-css' href='https://tools.cep.health/wp-content/plugins/glossary-by-codeat/assets/css/tooltip-classic.css?ver=2.3.5' media='all' />
<script type="text/javascript" src="https://tools.cep.health/wp-content/plugins/google-analytics-for-wordpress/assets/js/frontend-gtag.min.js?ver=9.5.3" id="monsterinsights-frontend-script-js" async="async" data-wp-strategy="async"></script>
<script data-cfasync="false" data-wpfc-render="false" type="text/javascript" id='monsterinsights-frontend-script-js-extra'>/* <![CDATA[ */
var monsterinsights_frontend = {"js_events_tracking":"true","download_extensions":"doc,pdf,ppt,zip,xls,docx,pptx,xlsx","inbound_paths":"[{\"path\":\"\\\/go\\\/\",\"label\":\"affiliate\"},{\"path\":\"\\\/recommend\\\/\",\"label\":\"affiliate\"}]","home_url":"https:\/\/tools.cep.health","hash_tracking":"true","v4_id":"G-G1F4BDXK7E"};/* ]]> */
</script>

<!-- Google tag (gtag.js) snippet added by Site Kit -->

<!-- Google Analytics snippet added by Site Kit -->
<script type="text/javascript" src="https://www.googletagmanager.com/gtag/js?id=GT-MBGGM43" id="google_gtagjs-js" async></script>
<script type="text/javascript" id="google_gtagjs-js-after">
/* <![CDATA[ */
window.dataLayer = window.dataLayer || [];function gtag(){dataLayer.push(arguments);}
gtag("set","linker",{"domains":["tools.cep.health"]});
gtag("js", new Date());
gtag("set", "developer_id.dZTNiMT", true);
gtag("config", "GT-MBGGM43");
/* ]]> */
</script>

<!-- End Google tag (gtag.js) snippet added by Site Kit -->
<script type="text/javascript" src="https://tools.cep.health/wp-content/themes/cep-tools/js/jquery.min.js" id="jquery-js"></script>
<script type="text/javascript" src="https://tools.cep.health/wp-content/themes/cep-tools/js/jquery-migrate.min.js" id="jquery-migrate-js"></script>
<link rel="https://api.w.org/" href="https://tools.cep.health/wp-json/" /><link rel="alternate" title="JSON" type="application/json" href="https://tools.cep.health/wp-json/wp/v2/tools/27345" /><link rel="alternate" title="oEmbed (JSON)" type="application/json+oembed" href="https://tools.cep.health/wp-json/oembed/1.0/embed?url=https%3A%2F%2Ftools.cep.health%2Ftool%2Ftype-2-diabetes-insulin-therapy%2F" />
<link rel="alternate" title="oEmbed (XML)" type="text/xml+oembed" href="https://tools.cep.health/wp-json/oembed/1.0/embed?url=https%3A%2F%2Ftools.cep.health%2Ftool%2Ftype-2-diabetes-insulin-therapy%2F&#038;format=xml" />
<meta name="generator" content="Site Kit by Google 1.155.0" />
<!-- Google Tag Manager snippet added by Site Kit -->
<script type="text/javascript">
/* <![CDATA[ */

			( function( w, d, s, l, i ) {
				w[l] = w[l] || [];
				w[l].push( {'gtm.start': new Date().getTime(), event: 'gtm.js'} );
				var f = d.getElementsByTagName( s )[0],
					j = d.createElement( s ), dl = l != 'dataLayer' ? '&l=' + l : '';
				j.async = true;
				j.src = 'https://www.googletagmanager.com/gtm.js?id=' + i + dl;
				f.parentNode.insertBefore( j, f );
			} )( window, document, 'script', 'dataLayer', 'GTM-WLFDZV' );
			
/* ]]> */
</script>

<!-- End Google Tag Manager snippet added by Site Kit -->
<link rel="icon" href="https://tools.cep.health/wp-content/uploads/2019/10/cropped-Frame-36-1-32x32.png" sizes="32x32" />
<link rel="icon" href="https://tools.cep.health/wp-content/uploads/2019/10/cropped-Frame-36-1-192x192.png" sizes="192x192" />
<link rel="apple-touch-icon" href="https://tools.cep.health/wp-content/uploads/2019/10/cropped-Frame-36-1-180x180.png" />
<meta name="msapplication-TileImage" content="https://tools.cep.health/wp-content/uploads/2019/10/cropped-Frame-36-1-270x270.png" />
		<style type="text/css" id="wp-custom-css">
			.m0 {margin-top:0; margin-bottom: 0}		</style>
		<!--- Error: No Google analytics ID found. Go to Site Options > Analytics to enter your ID. ---><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({"gtm.start":new Date().getTime(),event:"gtm.js"});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!="dataLayer"?"&l="+l:"";j.async=true;j.src="https://www.googletagmanager.com/gtm.js?id="+i+dl;f.parentNode.insertBefore(j,f);})(window,document,"script","dataLayer","GTM-K6HPX8H");</script>  </head>
  <body class="wp-singular tools-template-default single single-tools postid-27345 wp-theme-cep-tools type-2-diabetes-insulin-therapy">

      <!-- Google Tag Manager (noscript) -->
    <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-K6HPX8H"
    height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
    <!-- End Google Tag Manager (noscript) -->

    <header>
      <div class="container">
        <div class="columns is-flex is-gapless">
          <div class="column">
            <a class="logo" target="_self" href="https://cep.health/tools" data-wpel-link="external" rel="external noopener noreferrer">
              <img src="https://tools.cep.health/wp-content/themes/cep-tools/img/logo.svg" alt="Centre for Effective Practice - Digital Tools" />
            </a>
          </div>
        </div>
      </div>
    </header>

<main>
  	<section class="section--impact_area">
    <div class="container">
        <h1>Type 2 diabetes: insulin therapy</h1>
                    <p class="last-updated"><i class="icon icon-clock-with-arrow"> </i>Last Updated: June 23, 2023</p>
                <ul class="links">
            <li>
                <button data-search-content class="button">Search Content&nbsp;&nbsp;<i class="icon icon-search"></i></a>
            </li>
                    </ul>
    </div>
</section>

		<section class="section--sections_listing" id="sections">

			
<div class="search-tool">
    <div class="search-tool-bar">
        <div class="search-wrapper">
            <div class="search-input-wrapper">
                <input data-search-tool-input type="search" autocomplete="off" placeholder="Enter search terms">
                <i class="icon icon-search"></i>
                <span class="search-no-results-found">No Results Found</span>
                <span class="search-result-count"><span class="current">0</span>/<span class="total">0</span></span>
            </div>
            <button data-search-previous disabled class="search-previous"><i class="icon icon-chevron-up"></i></button>
            <button data-search-next disabled class="search-next"><i class="icon icon-chevron-down"></i></button>
        </div>
        <button data-search-tool-close class="close"><i class="icon icon-close"></i></button>
    </div>
</div>
			<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p>This tool is designed to support family physicians and primary care nurse practitioners to prescribe and manage insulin therapy for adult patients living with type 2 diabetes.</p>
</div></article>

<article class="block--background  core-block" data-block-name="cep/background"><div class="container">
<div class="wp-block-cep-background is-style-blue-background"><article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Checkmark-Large.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <h6><a href="https://cep.health/academic-detailing/" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Sign up for virtual academic detailing (one-on-one education) on this topic</a></h6>
          </div>
        </div>

      </div>
</article></div>
</div></article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p>For many patients with type 2 diabetes, insulin is needed eventually. As the condition progresses, non-insulin pharmacotherapy may no longer be sufficient to maintain glycemic control over time.<sup>1,2</sup></p>
</div></article>			<div class="container has-text-right" style="padding: 0 0 1.5rem;">
				<div class="expand-all">
					<a href="#" data-expand-text="Expand All" data-collapse-text="Collapse All">Expand All</a>
				</div>
			</div>
			<div id="top-of-sections"></div>
							<section class="main-section" id="overview-of-insulin-therapy-for-type-2-diabetes" tabindex="-1">
					<div class="head">
						<div class="container">
							<h2 class="main-heading">
								Overview of insulin therapy for type 2 diabetes								
							</h2>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
						</div>
					</div>
					<div class="body">
						<div class="container">
							<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p>If the desired glycemic goals cannot be reached using current antihyperglycemic medication(s) or if the patient&#8217;s medical condition changes, other agents should be considered (either added to the existing regimen or used as replacements) <a href="https://link.cep.health/t2dmnoninhtml5" data-type="URL" data-id="https://link.cep.health/t2dmnoninhtml5" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">to minimize cardiorenal complications and enhance glycemic management</a>.<sup>3-7</sup></p>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading">Glycemic approach<sup>1,2,8-10</sup></h3>
</div></article>

<article class="block--image  core-block" data-block-name="core/image"><div class="container">
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" src="https://tools.cep.health/wp-content/uploads/2023/07/CEP_InsulinTherapy_Overview-1024x865.png" alt="" class="wp-image-60105" width="1128" height="953" srcset="https://tools.cep.health/wp-content/uploads/2023/07/CEP_InsulinTherapy_Overview-1024x865.png 1024w, https://tools.cep.health/wp-content/uploads/2023/07/CEP_InsulinTherapy_Overview-300x254.png 300w, https://tools.cep.health/wp-content/uploads/2023/07/CEP_InsulinTherapy_Overview-768x649.png 768w, https://tools.cep.health/wp-content/uploads/2023/07/CEP_InsulinTherapy_Overview-1536x1298.png 1536w, https://tools.cep.health/wp-content/uploads/2023/07/CEP_InsulinTherapy_Overview-2048x1731.png 2048w, https://tools.cep.health/wp-content/uploads/2023/07/CEP_InsulinTherapy_Overview-1704x1440.png 1704w, https://tools.cep.health/wp-content/uploads/2023/07/CEP_InsulinTherapy_Overview-1278x1080.png 1278w, https://tools.cep.health/wp-content/uploads/2023/07/CEP_InsulinTherapy_Overview-852x720.png 852w, https://tools.cep.health/wp-content/uploads/2023/07/CEP_InsulinTherapy_Overview-568x480.png 568w" sizes="auto, (max-width: 1128px) 100vw, 1128px" /></figure>
</div></article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p style="font-size:12px">* Functionally dependent patients have a <a href="https://link.cep.health/t2dminhmtl80" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Clinical Frailty Scale</a><sup>11</sup> score of 4-5 on a 9-point scale. Patients with frailty have a <a href="https://link.cep.health/t2dminhmtl80" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Clinical Frailty Scale</a><sup>11</sup> score of 6-8 on a 9-point scale.<br>** Some experts suggest using early, short-term (2-4 weeks) intensive insulin therapy in newly diagnosed type 2 diabetes patients with symptomatic hyperglycemia or those with high cardiovascular risk in acute care settings (e.g., acute MI, stroke, coronary artery bypass graft). This approach is associated with improvements in insulin resistance, beta cell function, quality of life and may induce remission when started within the first 2 years of diagnosis. It reflects expert opinion and is not included in current clinical practice guidelines.<sup>12,13</sup><br>† And titrate dose of GLP1-RA as tolerated<br>†† Or fixed-ratio combination<br>††† If eGFR &gt;30ml/min/1.73m2, may be used for cardiorenal benefit<br>Notes: DPP4i = dipeptidyl peptidase-4 inhibitor, eGFR = estimated glomerular filtration rate, GLP1-RA = glucagon-like peptide-1 receptor agonist, SGLT2i = sodium-glucose cotransporter-2 inhibitor<br><strong>Bold</strong> = agents with stronger evidence</p>
</div></article>

<article class="block--table ">
<div class="container">
  <div class="table  inner-border-blue blue">

                    <header>
                <h3>Different types of insulin</h3>
            </header>
        
                    <div class="rows">

                                    <div class="row">

                                                    <div class="cols">
                        
                                
                                                                            <div class="col 1" style="flex-basis:33%;">
                                            <h5><img loading="lazy" decoding="async" class="alignleft" src="https://tools.cep.health/wp-content/uploads/2021/04/1.png" alt="" width="30" height="28" /> Basal insulin</h5>
<h6><strong>What it is</strong></h6>
<ul>
<li>I<span dir="ltr">ntermediate- or long-acting insulin, </span><span dir="ltr">usually injected once daily (usually </span><span dir="ltr">at bedtime) and used to keep blood </span><span dir="ltr">glucose levels stable during periods </span><span dir="ltr">of fasting (e.g., between meals, while </span><span dir="ltr">sleeping</span></li>
</ul>
<h6><strong>When to use it</strong></h6>
<ul>
<li>First-line treatment for insulin-naive patients<sup>2</sup></li>
<li>It is a simpler treatment regimen that causes less hypoglycemia and weight gain compared to premixed insulin or prandial-only regimens<sup>2</sup></li>
</ul>
<h6></h6>
<h6>Jump to: <a href="#basaloptions">Basal insulin options</a></h6>
                                        </div>
                                    
                                
                                                                            <div class="col 2" style="flex-basis:33%;">
                                            <h5><img loading="lazy" decoding="async" class="alignleft" src="https://tools.cep.health/wp-content/uploads/2021/04/2.png" alt="" width="30" height="28" /> Prandial (bolus) insulin</h5>
<h6><strong>What it is<br />
</strong></h6>
<ul>
<li>Short- or rapid-acting insulin injected at mealtime to control post-prandial (post-meal) glucose levels or for short-term correction of meal-related hyperglycemia</li>
</ul>
<h6><strong>When to use it</strong></h6>
<ul>
<li>May be added at mealtimes if glycemic control is suboptimal after 3-6 months on basal insulin (with other agents)<sup>14</sup></li>
<li>Basal and prandial (bolus) insulin may be started together if the patient’s blood glucose level is high (≥16.7 mmol/L) and metabolic decompensation is present at initial diagnosis<sup>1</sup></li>
</ul>
<h6></h6>
<h6>Jump to: <a href="#bolus">Prandial (bolus) insulin options</a></h6>
                                        </div>
                                    
                                
                                                                            <div class="col 3" style="flex-basis:33%;">
                                            <h5><img loading="lazy" decoding="async" class="alignleft" src="https://tools.cep.health/wp-content/uploads/2021/04/3.png" alt="" width="30" height="28" /> Premixed insulin</h5>
<h6><strong>What it is<br />
</strong></h6>
<ul>
<li>Premixed solutions that contain two types of insulin (e.g., prandial and basal insulin)</li>
</ul>
<h6><strong>When to use it</strong></h6>
<ul>
<li><span dir="ltr">Cons</span><span dir="ltr">ider for patients who cannot </span><span dir="ltr">accommodate &gt; 2 injections/day (e.g., </span><span dir="ltr">those who require home care/caregiver </span><span dir="ltr">support to administer insulin), or patients </span><span dir="ltr">who would have difficulty adjusting </span><span dir="ltr">insulin doses (e.g., due to cognitive ability</span> <span dir="ltr">o</span><span dir="ltr">r</span><span dir="ltr"> visual acuity)</span><sup><span dir="ltr">15,16</span></sup></li>
<li><span dir="ltr">This dosing option is less flexible </span><span dir="ltr">(requires a routine mealtime to prevent </span><span dir="ltr">hypoglycemia) and offers less ability to </span><span dir="ltr">correct for abnormal results</span><sup>15</sup></li>
</ul>
<h6></h6>
<h6>Jump to: <a href="#premixedoptions">Premixed insulin options</a></h6>
                                        </div>
                                    
                                                            </div>
                        
                    </div>
                                    <div class="row">

                                                    <div class="cols">
                        
                                
                                                                            <div class="col 1" style="flex-basis:33%;">
                                            <p><img loading="lazy" decoding="async" class="" src="https://tools.cep.health/wp-content/uploads/2021/04/chart-updated.png" alt="" width="1149" height="412" /></p>
                                        </div>
                                    
                                                            </div>
                        
                    </div>
                
            </div>
        
        
    </div>
</div>
</article>						</div>
					</div>
				</section>
							<section class="main-section" id="selecting-an-insulin" tabindex="-1">
					<div class="head">
						<div class="container">
							<h2 class="main-heading">
								Selecting an insulin								
							</h2>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
						</div>
					</div>
					<div class="body">
						<div class="container">
							<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>There is not a simple reason to choose one insulin over another, within each type of insulin (basal, prandial and combination)</li>



<li>When comparing insulin options, prioritize a patient’s preference in the shared decision-making process</li>
</ul>
</div></article>

<article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Checkmark-Large.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <h3>Common properties of insulin</h3>
          </div>
        </div>

      </div>
</article>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h5 class="wp-block-heading">A1C reduction</h5>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Effect on A1C is 0.9-1.2% or more<sup>2</sup></li>



<li>A1C reduction depends on dose and number of injections per day<sup>14</sup></li>



<li>Dose increases may be limited by hypoglycemia and cost<sup>2</sup></li>
</ul>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h5 class="wp-block-heading">Impact on weight</h5>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>All insulin associated with weight gain:<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Effects on weight are dose-related</li>



<li>Basal insulin is associated with a weight gain of 1-2 kg* (over 6-12 months)<sup>2,17-19</sup><article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Detemir and glargine 300 units/mL may lead to slightly less weight gain (≤1kg) than other options<sup>20,21</sup></li>
</ul>
</div></article></li>



<li>Prandial (bolus) insulin is associated with a weight gain (exact amount unknown)<sup>2</sup></li>



<li>Premixed insulins are associated with a weight gain of 3.5-5 kg <span class="tooltip-wrapper"><span class="tooltip-parent">(over 6-12 months)Unclear if it is causation or correlation</span></span><sup>2,17-19</sup></li>
</ul>
</div></article></li>
</ul>
</div></article></div>



<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h5 class="wp-block-heading">Cardiorenal outcomes</h5>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Insulin has a neutral effect on cardiorenal outcomes (safety but no risk reduction)<sup>1,2,22-24</sup></li>
</ul>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h5 class="wp-block-heading">Harms</h5>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Hypoglycemia</li>



<li>Lipohypertrophy</li>



<li>Local injection site reactions (exception: fewer with glargine vs. detemir)<sup>25</sup></li>



<li>Allergic reactions (rare)<sup>1</sup></li>
</ul>
</div></article></div>
</div>


<article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Checkmark-Large.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <h3>Insulin specific properties</h3>
          </div>
        </div>

      </div>
</article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h5 class="wp-block-heading">Onset, peak and duration of action</h5>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>See <a href="#insulinspecificprop">Insulin options</a> for more information </li>
</ul>
</div></article>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow" style="flex-basis:66.66%"><article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h5 class="wp-block-heading">Cost and coverage</h5>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Cost is an important factor for many patients</li>



<li>Balance the consideration of cost against other factors when selecting insulin in the shared decision-making process</li>



<li>Patients’ coverage (e.g., Ontario Drug Benefit [ODB], Non-Insured Health Benefits [NIHB]) plays into cost</li>



<li><strong>Originator biologic insulin lispro (Humalog 100 units/mL dosage forms), insulin aspart (NovoRapid), and insulin glargine (Lantus) will not be covered through the ODB as of December 29, 2023 without a medically necessary exemption</strong><sup>26</sup></li>
</ul>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h5 class="wp-block-heading">Hypoglycemia risk (for basal insulin)<sup>27-29</sup></h5>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Some patients benefit from choosing long-acting insulin over intermediate-acting insulin (e.g., those who do shift work, have inconsistent oral intake or those who would benefit from dosing less often)</li>



<li>For most patients, however, choosing basal insulin is not the primary factor in reducing hypoglycemia risk in a clinically meaningful way (i.e., absolute risk differences are small and the evidence is limited, making it difficult to compare basal insulins with confidence)</li>



<li>Determining other ways to reduce hypoglycemia risk is essential (see <a href="#managing-hypoglycemia">Managing hypoglycemia</a>)</li>
</ul>
</div></article>

<article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Checkmark-Large.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <h3>Other properties<sup>20,21,30,31</sup></h3>
          </div>
        </div>

      </div>
</article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li><span class="tooltip-wrapper"><span class="tooltip-parent">Mortality</span><span class="tooltip-content">Not well studied</span></span> (exception for prandial: studies have not shown a significant difference in mortality between rapid- and short-acting insulin)<sup>32</sup></li>



<li><span class="tooltip-wrapper"><span class="tooltip-parent">Quality of life</span><span class="tooltip-content">Not well studied</span></span></li>



<li>Environmental impact of insulin</li>
</ul>
</div></article>

<article class="block--modal ">

<div class="outer">
  <div class="container">
    <div class="inner has-text-centered">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2021/04/vectors_sharpscontainer.png" alt="" />
                    <h6>Consider the environmental impact of insulin</h6>
                          <a data-modal="eYkjB0" class="button open-modal" href="#" data-id="eYkjB0">Click for details</a>
          </div>
  </div>
</div>

  <div data-modal="eYkjB0" class="modal">
    <div class="inner text">
      <div class="close-wrapper">
                <a href="" class="close" data-wpel-link="internal">Close</a>
      </div>
      <div class="container">
                <div class="content">
          
                          <h4>Consider the environmental impact of insulin</h4>
                                      <p>The environmental impact of insulin is important to some patients.</p>
<h6></h6>
<h6>Suggestions to reduce the environmental impact of insulin include:</h6>
<ul>
<li>Consider reusable insulin pens instead of single-use, prefilled insulin pens if available (see <a href="https://tools.cep.health/tool/type-2-diabetes-insulin-therapy/#insulin-options-basal-prandial-premixed" data-wpel-link="internal">Insulin specific properties tables</a> for insulin products that have reusable pens that take cartridges)<sup>45,47,48</sup></li>
<li>Disposing of pens, syringes, needles and cartridges in a clearly-labeled, closable, puncture-resistant sharps container (can be obtained from a pharmacy) to prevent the disposal of ‘sharps’ into landfills<sup>48-50</sup></li>
<li>If patients are using insulin exceeding amount allowed in 1 injection, consider a more concentrated insulin formulation (less volume required) and counsel the patient on appropriate dosing to avoid overdose<sup>45,46,49,51</sup></li>
<li>Recycle the paper boxes, pamphlets and inserts packaged with insulin<sup>52</sup></li>
</ul>
            
                  </div>
      </div>
    </div>
    <div class="overlay"></div>
</div></article></div>



<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow" style="flex-basis:33.33%"><article class="block--modal ">

<div class="outer">
  <div class="container">
    <div class="inner has-text-centered">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2020/05/info-icon.svg" alt="" />
                    <h6>Biosimilar insulins</h6>
                          <a data-modal="MKxBU6" class="button open-modal" href="#" data-id="MKxBU6">Click for details</a>
          </div>
  </div>
</div>

  <div data-modal="MKxBU6" class="modal">
    <div class="inner text">
      <div class="close-wrapper">
                <a href="" class="close" data-wpel-link="internal">Close</a>
      </div>
      <div class="container">
                <div class="content">
          
                          <h4>Biosimilar insulins<sup>33-42</sup></h4>
                                      <p>As of March 31, 2023, patients who are eligible for ODB program benefits and using insulin lispro (Humalog), insulin aspart (NovoRapid), and insulin glargine (Lantus) are required to transition to a biosimilar. This is a 1:1 &#8211; same dose switch.</p>
<p>A biosimilar is a biologic drug that is highly similar to a biologic drug that was already authorized for sale. At a reduced cost, biosimilars have equivalent clinical efficacy and safety as their originator biologic drug.</p>
<p>Originator biologic insulins listed above will not be covered through the ODB as of December 29, 2023, unless patients have been approved for a medically necessary exemption. To avoid gaps in coverage, during the 9-month transition period that ends in December 2023, ODB will cover both the originator and biosimilar options for patients currently receiving insulin therapy. The transition period will provide time for health care providers to become informed and subsequently have discussions with patients about biosimilar transition. This transition period will also allow time for prescribers to write a new prescription and provide time for patients to obtain their new insulin and, in some-cases, new insulin pens from their pharmacy.</p>
<p>Below are the biosimilar insulins that are available in Ontario:</p>
<p><img decoding="async" src="https://tools.cep.health/wp-content/uploads/2023/06/CEP_InsulinTherapy_June21-chart.png" /></p>
<p><b>For insulin-naive patients</b>, consider biosimilar insulins in the table above as the first treatment option given their cost-effective advantage.</p>
<p><b>For patients on an established insulin therapy and requiring a switch to a biosimila</b>r, consider the following approach. Submit a claim for K900A when switching patients from an originator biologic insulin to a biosimilar to receive a support payment of $61.20.</p>
<p><img loading="lazy" decoding="async" class="aligncenter" src="https://tools.cep.health/wp-content/uploads/2023/07/CEP_InsulinTherapy_BiosimilarPathway_July11-1-e1689174338405.png" alt="selecting insulin&gt;biosimilar insulin" width="660" height="954" /></p>
<p><sub><strong>*</strong>For patients awaiting medically necessary exemption via the EAP that were already established on originator insulins therapy before March 2023; </sub><sub><strong>**</strong>For patients established on therapy prior to March 31, 2023 who is or has become pregnant during the biosimilar transition period between March 31, 2023 to December 28, 2023; </sub><sub><strong>***</strong>For patients established on therapy prior to March 31, 2023 who is or becomes palliative requiring end-of-life care during the biosimilar transition period between March 31, 2023 to December 28, 2023.</sub></p>
<p>Click <a href="https://link.cep.health/t2dminhtml55" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">here</a> for EMR queries to identify patients who are ODB program recipients and currently prescribed NovoRapid, Humalog, and Lantus.</p>
<p><em>The patient&#8217;s new biosimilar insulin pen(s) may look different from the originator insulin. Encourage patients to consult their pharmacist to minimize confusion about the change in appearance, especially if they use different pens for basal and bolus therapy. If switching both basal and bolus therapy to biosimilars, consider temporally separate switches to reduce medication errors.</em></p>
<h6>Medically necessary exemptions</h6>
<p>To ensure no gaps in patient coverage through the ODB, submit EAP requests promptly through the <a href="https://link.cep.health/t2dminhtml59" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Special Authorization Digital Information Exchange</a>. Requests can also be faxed using the <a href="https://link.cep.health/t2dminhtml60" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">EAP form</a> to 1-866-811-9908 (toll-free) or 416-327-7526 (Toronto area)</p>
            
                  </div>
      </div>
    </div>
    <div class="overlay"></div>
</div></article>

<article class="block--modal ">

<div class="outer">
  <div class="container">
    <div class="inner has-text-centered">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/talking-points.svg" alt="" />
                    <h6>Biosimilar insulins talking tips</h6>
                          <a data-modal="CoKxiB" class="button open-modal" href="#" data-id="CoKxiB">Click to view</a>
          </div>
  </div>
</div>

  <div data-modal="CoKxiB" class="modal">
    <div class="inner text">
      <div class="close-wrapper">
                <a href="" class="close" data-wpel-link="internal">Close</a>
      </div>
      <div class="container">
                <div class="content">
          
                          <h4>Biosimilar insulins talking tips <sup>36-39</sup></h4>
                                      <ul>
<li aria-level="1">This new insulin has been approved and reviewed by Health Canada and is basically the same as your previous one.</li>
<li aria-level="1">Although your new biosimilar insulin pen may look and feel a little bit different, it still works the same as the insulin you were taking.</li>
<li aria-level="1">Use this new insulin the exact same way and same dose as your previous one. Continue all your other medications the same way too.</li>
<li aria-level="1">When you get your prescription filled for the first time, ask your pharmacist to show you how to attach the needles and inject. You can also reach out to them if you have any more ongoing questions.</li>
<li aria-level="1">[For patients who are not supposed to switch to a biosimilar insulin &#8211; i.e., those who have characteristics or circumstances, temporary or otherwise, that would contribute to negatively impacting health outcomes] I need to add an extra code to your prescription so you can stay on this medication.</li>
<li aria-level="1">Originator biologic insulin lispro (Humalog 100 units/mL dosage forms), insulin aspart (NovoRapid), and insulin glargine (Lantus) will not be covered through the ODB as of December 29, 2023 without a medically necessary exemption.</li>
</ul>
            
                  </div>
      </div>
    </div>
    <div class="overlay"></div>
</div></article>

<article class="block--modal ">

<div class="outer">
  <div class="container">
    <div class="inner has-text-centered">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2021/04/reimbursement.png" alt="" />
                    <h6>Consider the affordability of insulin</h6>
                          <a data-modal="6jLDpc" class="button open-modal" href="#" data-id="6jLDpc">Click for details</a>
          </div>
  </div>
</div>

  <div data-modal="6jLDpc" class="modal">
    <div class="inner text">
      <div class="close-wrapper">
                <a href="" class="close" data-wpel-link="internal">Close</a>
      </div>
      <div class="container">
                <div class="content">
          
                          <h4>Consider the affordability of insulin<sup>57</sup></h4>
                                      <ul>
<li>All insulin options below have ODB and NIHB coverage unless otherwise specified</li>
<li>All insulin 100 units/mL, unless otherwise specified</li>
</ul>
<p><img loading="lazy" decoding="async" class="alignnone" src="https://tools.cep.health/wp-content/uploads/2024/07/CEP_InsulinMedTable_July262024.png" width="1000" height="1250" /></p>
<p><em>* Prices reflect the cost to the customer and include markup and dispensing fee (the cost per dosage form and the 100-day cost both include one dispensing fee and reflect the usual pharmacy practice of dispensing a full box; e. g., 5x3mL pens). The cost for a usual dose assumes a 100kg patient.</em><br data-rich-text-line-break="true" /><em>** See <a href="#insulinspecificprop">Insulin Options</a> cards for details on the limited use restrictions.</em></p>
            
                  </div>
      </div>
    </div>
    <div class="overlay"></div>
</div></article>

<article class="block--modal ">

<div class="outer">
  <div class="container">
    <div class="inner has-text-centered">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2021/04/money.png" alt="" />
                    <h6>Explore patient reimbursement opportunities for insulin related supplies</h6>
                          <a data-modal="XRGZPH" class="button open-modal" href="#" data-id="XRGZPH">Click for details</a>
          </div>
  </div>
</div>

  <div data-modal="XRGZPH" class="modal">
    <div class="inner text">
      <div class="close-wrapper">
                <a href="" class="close" data-wpel-link="internal">Close</a>
      </div>
      <div class="container">
                <div class="content">
          
                          <h4>Reimbursement opportunities</h4>
                                      <p>Support patients to explore reimbursement opportunities for blood glucose monitoring supplies, pen needles and syringes.</p>
<h6><strong>Ontario Ministry of Health’s Ontario Drug Benefit (ODB) program</strong></h6>
<ul>
<li>Offers all ODB recipients on insulin <a href="https://link.cep.health/t2dminhtml2" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">reimbursement for a flash glucose monitoring system</a> (specifically, the FreeStyle Libre and FreeStyle Libre 2 systems), including:
<ul>
<li>1 reader/patient (otherwise costs $65)</li>
<li>33 sensors/year/patient (otherwise costs $2,457.54/year)</li>
</ul>
</li>
<li>Offers all ODB recipients coverage for a set <a href="https://link.cep.health/t2dminhtml3" data-type="URL" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">number of blood glucose test</a> strips annually, depending on their diabetes management approach:
<ul>
<li>3,000 test strips/year for patients on insulin</li>
<li>400 test strips/year for patients on non-insulin pharmacotherapy with higher risk of causing hypoglycemia (e.g., glyburide, gliclazide)</li>
<li>200 test strips/year for patients on non-insulin pharmacotherapy with lower risk of causing hypoglycemia (e.g., acarbose, metformin, canagliflozin, empagliflozin, linagliptin, saxagliptin, sitagliptin)</li>
<li>200 test strips/year for patients on diet/lifestyle therapy only</li>
</ul>
</li>
</ul>
<h6><strong>Diabetes Canada’s Ontario Monitoring for Health Program<sup>14</sup></strong></h6>
<p>Offers patients of all ages 75% <a href="https://link.cep.health/t2dminhtml4" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">reimbursement for</a>:</p>
<ul>
<li>Blood glucose test strips and lancets – up to a maximum of $920/year</li>
<li>Blood glucose meter – up to a maximum of $75/every 5 years</li>
<li>Talking blood glucose meter – up to a maximum of $300/every 5 years (note: a letter from a doctor is required to confirm visual impairment)</li>
</ul>
<h6><strong>Ontario Ministry of Health’s Assistive Devices Program<sup>43</sup></strong></h6>
<ul>
<li>Offers patients 65+ an annual grant ($170/year) to <a href="https://link.cep.health/t2dminhtml5" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">cover the costs of needles and syringes</a> used to inject insulin</li>
<li>Consider less expensive insulin dosage forms (e.g., vials) for patients 65+ who obtain syringe coverage</li>
</ul>
<p>&nbsp;</p>
<h6><strong>Non-Insured Health Benefits Program<sup>44</sup></strong></h6>
<ul>
<li>Starting April 25, 2023, the NIHB Program will include coverage for Dexcom G6, FreeStyle Libre, and FreeStyle Libre 2 CGM systems as limited use benefits for patients managing insulin-dependent diabetes</li>
<li>Prior approval and coverage criteria listed in the Drug Benefit List apply</li>
<li>NIHB also covers diabetes test strips, allowing up to 800 strips per 100 days for insulin-managing patients</li>
<li>Coverage allows for one reader every three years and 14 sensors every six months</li>
</ul>
            
                  </div>
      </div>
    </div>
    <div class="overlay"></div>
</div></article></div>
</div>


<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading" id="insulinspecificprop">Insulin options</h3>
</div></article>

<article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Eye.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <h6><a href="https://link.cep.health/t2dminhtml81" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">View in table format</a></h6>
          </div>
        </div>

      </div>
</article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h5 class="wp-block-heading" id="basaloptions">Basal insulin<sup>1,15,46,53-59,103</sup></h5>
</div></article>

<article class="block--drug-options ">
<div class="container">
  <h5><span style="font-size: 13.5px;">Scroll (left-right) for details</h5>
          <div class="slider">
        <div class="inner-stage">
          <ul>
            
                <li>
                  <div class="inner">
                    <span class="subhead">Intermediate acting</span>
                    <h6>NPH (Humulin<sup>®</sup> N)</h6>
                    <p><em>100 units/mL</em></p>
<p><strong>Activity profile</strong></p>
<ul>
<li>Onset<strong>:</strong>1-2h</li>
<li>Peak<strong>: </strong>5-8h</li>
<li>Duration<strong>: </strong>14-18h</li>
</ul>
<p><strong>Coverage</strong></p>
<ul>
<li>ODB ✓</li>
<li>NIHB ✓</li>
</ul>
<p><strong>Dosage forms</strong></p>
<ul>
<li>5x3mL prefilled pens</li>
<li>5x3mL cartridges</li>
<li>10mL vial</li>
</ul>
<p><strong>Cost for usual dose (50 units/day for 100 days supply; basal alone)*</strong></p>
<ul>
<li>3mL prefilled pens: $204</li>
<li>3mL cartridges: $204</li>
<li>10mL vial: $158</li>
</ul>
<p><strong>Cost for usual dose (25 units/day for 100 days supply; basal + bolus; cost is for basal component)*</strong></p>
<ul>
<li>3mL prefilled pens: $107</li>
<li>3mL cartridges: $107</li>
<li>10mL vial: $84</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="dT51LK">Comments</a>
                                      </div>
                                      <div class="modal" data-modal="dT51LK">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Comments</h4>
                                                                                      <ul>
<li>More erratic absorption vs. long-acting analogues</li>
<li>If a patient is dosed bid, the need for a lunch dose of prandial (bolus) insulin may be delayed</li>
<li>Max units/dose: 60 for prefilled and reusable <span class="tooltip-wrapper"><span class="tooltip-parent">pens</span><span class="tooltip-content">This reflects the maximum amount given for 1 injection, not the maximum amount of insulin that is required. Multiple injections may be required to achieve blood glucose targets.</span></span></li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Intermediate acting</span>
                    <h6>NPH (Novolin<sup>®</sup> ge)</h6>
                    <p><em>100 units/mL</em></p>
<p><strong>Activity profile</strong></p>
<ul>
<li>Onset: 1-2h</li>
<li>Peak: 5-8h</li>
<li>Duration: 14-18h</li>
</ul>
<p><strong>Coverage</strong></p>
<ul>
<li>ODB ✓</li>
<li>NIHB ✓</li>
</ul>
<p><strong>Dosage forms</strong></p>
<ul>
<li>5x3mL cartridges</li>
<li>10mL vial</li>
</ul>
<p><strong>Cost for usual dose (50 units/day for 100 days supply; basal alone)*</strong></p>
<ul>
<li>3mL cartridges: $188</li>
<li>10mL vial: $145</li>
</ul>
<p><strong>Cost for usual dose (25 units/day for 100 days supply; basal + bolus; cost is for basal component)*</strong></p>
<ul>
<li>3mL prefilled pens: $98</li>
<li>10mL vial: $77</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="fJ9RVS">Comments</a>
                                      </div>
                                      <div class="modal" data-modal="fJ9RVS">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Comments</h4>
                                                                                      <ul>
<li>More erratic absorption vs. long-acting analogues</li>
<li>If a patient is dosed bid, the need for a lunch dose of prandial (bolus) insulin may be delayed</li>
<li>Max units/dose: 60 for prefilled and reusable <span class="tooltip-wrapper"><span class="tooltip-parent">pens</span><span class="tooltip-content">This reflects the maximum amount given for 1 injection, not the maximum amount of insulin that is required. Multiple injections may be required to achieve blood glucose targets.</span></span></li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Intermediate acting</span>
                    <h6>NPH pork (Hypurin<sup>®</sup>)</h6>
                    <p><em>100 units/mL</em></p>
<p><em>Not on Ontario drug formulary</em></p>
<p><strong>Activity profile</strong></p>
<ul>
<li>Onset: 1-3h</li>
<li>Peak: 6-12h</li>
<li>Duration: 24-48h</li>
</ul>
<p><strong>Coverage</strong></p>
<ul>
<li>ODB X</li>
<li>NIHB X</li>
</ul>
<p><strong>Dosage forms</strong></p>
<ul>
<li>10mL vial</li>
</ul>
<p><strong>Cost for usual dose (50 units/day for 100 days supply; basal alone)*</strong></p>
<ul>
<li>$718</li>
</ul>
<p><strong>Cost for usual dose (25 units/day for 100 days supply; basal + bolus; cost is for basal component)*</strong></p>
<ul>
<li>$355</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="ALJ8SB">Comments</a>
                                      </div>
                                      <div class="modal" data-modal="ALJ8SB">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Comments</h4>
                                                                                      <ul>
<li>Not often used in practice due to lack of coverage, cost and inconvenience  with vial/syringes</li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Long-acting</span>
                    <h6> Degludec (Tresiba<sup>®</sup>)</h6>
                    <p><em>100 units/mL</em></p>
<p><strong>Activity profile</strong></p>
<ul>
<li>Onset: 1h</li>
<li>Peak: No peak</li>
<li>Duration: 42h</li>
</ul>
<p><strong>Coverage</strong></p>
<ul>
<li>ODB ✓</li>
<li>NIHB ✓</li>
</ul>
<p><strong>Dosage forms</strong></p>
<ul>
<li>5x3mL prefilled pens</li>
</ul>
<p><strong>Cost for usual dose (50 units/day for 100 days supply; basal alone)*</strong></p>
<ul>
<li>$418</li>
</ul>
<p><strong>Cost for usual dose (25 units/day for 100 days supply; basal + bolus; cost is for basal component)*</strong></p>
<ul>
<li>$213</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="DcNCEA">Comments</a>
                                      </div>
                                      <div class="modal" data-modal="DcNCEA">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Comments</h4>
                                                                                      <ul>
<li>Duration useful for shift workers</li>
<li>Can increase the dose by increments of 1 unit</li>
<li>Max units/dose: 80 for prefilled <span class="tooltip-wrapper"><span class="tooltip-parent">pen</span><span class="tooltip-content">This reflects the maximum amount given for 1 injection, not the maximum amount of insulin that is required. Multiple injections may be required to achieve blood glucose targets.</span></span></li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Long-acting</span>
                    <h6>Degludec (Tresiba<sup>®</sup>)</h6>
                    <p><em>200 units/mL</em></p>
<p><strong>Activity profile</strong></p>
<ul>
<li>Onset: 1h</li>
<li>Peak: No peak</li>
<li>Duration: 42h</li>
</ul>
<p><strong>Coverage</strong></p>
<ul>
<li>ODB ✓</li>
<li>NIHB ✓</li>
</ul>
<p><strong>Dosage forms</strong></p>
<ul>
<li>3x3mL prefilled pens</li>
</ul>
<p><strong>Cost for usual dose (50 units/day for 100 days supply; basal alone)*</strong></p>
<ul>
<li>$418</li>
</ul>
<p><strong>Cost for usual dose (25 units/day for 100 days supply; basal + bolus; cost is for basal component)*</strong></p>
<ul>
<li>$213</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="eujQoq">Comments</a>
                                      </div>
                                      <div class="modal" data-modal="eujQoq">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Comments</h4>
                                                                                      <ul>
<li>Duration useful for shift workers</li>
<li>200 units/mL can be started if larger doses are required</li>
<li>Can increase the dose by increments of 2 units</li>
<li><span dir="ltr">Bioequivalent to degludec 100 units/mL</span></li>
<li>Max units/dose: 160 for prefilled <span class="tooltip-wrapper"><span class="tooltip-parent">pen</span><span class="tooltip-content">This reflects the maximum amount given for 1 injection, not the maximum amount of insulin that is required. Multiple injections may be required to achieve blood glucose targets.</span></span></li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Long-acting</span>
                    <h6>Detemir  (Levemir<sup>®</sup>)</h6>
                    <p><em>100 units/mL</em></p>
<p><strong>Activity profile</strong></p>
<ul>
<li>Onset: 1.5h</li>
<li>Peak: Flat, no discernable peak</li>
<li>Duration: 6-24h</li>
</ul>
<p><strong>Coverage</strong></p>
<ul>
<li>ODB ✓</li>
<li>NIHB ✓</li>
</ul>
<p><strong>Dosage forms</strong></p>
<ul>
<li>5x3mL cartridges</li>
</ul>
<p><strong>Cost for usual dose (50 units/day for 100 days supply; basal alone)*</strong></p>
<ul>
<li>$414</li>
</ul>
<p><strong>Cost for usual dose (25 units/day for 100 days supply; basal + bolus; cost is for basal component)*</strong></p>
<ul>
<li>$213</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="8cuToB">Comments</a>
                                      </div>
                                      <div class="modal" data-modal="8cuToB">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Comments</h4>
                                                                                      <ul>
<li>Duration of action may be shorter at lower doses and may require bid dosing (cut-off varies by patient)</li>
<li>If a patient is experiencing nocturnal hypoglycemia with a bedtime dose, lower the dose, inject the dose in the morning or split daily dose to bid</li>
<li>Max units/dose: 80 for prefilled pen,  60 for reusable <span class="tooltip-wrapper"><span class="tooltip-parent">pen</span><span class="tooltip-content">This reflects the maximum amount given for 1 injection, not the maximum amount of insulin that is required. Multiple injections may be required to achieve blood glucose targets.</span></span></li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Long-acting</span>
                    <h6>Glargine (Basaglar<sup>TM</sup>) </h6>
                    <p><em>100 units/mL</em></p>
<p><strong>Activity profile</strong></p>
<ul>
<li>Onset: 1.5h</li>
<li>Peak: Flat, no discernable peak</li>
<li>Duration: 24h</li>
</ul>
<p><strong>Coverage</strong></p>
<ul>
<li>ODB ✓</li>
<li>NIHB ✓</li>
</ul>
<p><strong>Dosage forms</strong></p>
<ul>
<li>5x3mL prefilled pens</li>
<li>5x3mL cartridges</li>
</ul>
<p><strong>Cost for usual dose (50 units/day for 100 days supply; basal alone)*</strong></p>
<ul>
<li>3mL prefilled pens: $288</li>
<li>3mL cartridges: $288</li>
</ul>
<p><strong>Cost for usual dose (25 units/day for 100 days supply; basal + bolus; cost is for basal component)*</strong></p>
<ul>
<li>3mL prefilled pens: $148</li>
<li>3mL cartridges: $148</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="Mi7fMb">Comments</a>
                                      </div>
                                      <div class="modal" data-modal="Mi7fMb">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Comments</h4>
                                                                                      <ul>
<li>Acidic formulation may cause irritation</li>
<li>Basaglar<sup>TM</sup> and Semglee<sup>®</sup> are biosimilars to Lantus<sup>®</sup><span style="font-size: 1.5rem;">  </span></li>
<li>If a patient is experiencing nocturnal hypoglycemia with a bedtime dose, lower the dose or inject the dose in the morning</li>
<li>Max units/dose: 80 for prefilled pens, 60 for Basaglar<sup>TM</sup> reusable <span class="tooltip-wrapper"><span class="tooltip-parent">pen</span><span class="tooltip-content">This reflects the maximum amount given for 1 injection, not the maximum amount of insulin that is required. Multiple injections may be required to achieve blood glucose targets.</span></span></li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Long-acting</span>
                    <h6>Glargine (Lantus<sup>®</sup>) </h6>
                    <p><em>100 units/mL</em></p>
<p><strong>Activity profile</strong></p>
<ul>
<li>Onset: 1.5h</li>
<li>Peak: Flat, no discernable peak</li>
<li>Duration: 24h</li>
</ul>
<p><strong>Coverage</strong></p>
<ul>
<li>ODB ✓ (<a href="https://link.cep.health/t2dminhtml52" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Limited use: 614, 642, 643</a> [prefilled pens and cartridges]), (LU <a href="http://link.cep.health/t2dminhtml61" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">642, 643, 644</a> [vial])</li>
<li>NIHB ✓</li>
</ul>
<p><strong>Dosage forms</strong></p>
<ul>
<li>5x3mL prefilled pens</li>
<li>5x3mL cartridges</li>
<li>10mL vial</li>
</ul>
<p><strong>Cost for usual dose (50 units/day for 100 days supply; basal alone)*</strong></p>
<ul>
<li>3mL prefilled pens: $349</li>
<li>3mL cartridges: $349</li>
<li>10mL vial: $348</li>
</ul>
<p><strong>Cost for usual dose (25 units/day for 100 days supply; basal + bolus; cost is for basal component)*</strong></p>
<ul>
<li>3mL prefilled pens: $179</li>
<li>3mL cartridges: $179</li>
<li>10mL vial: $178</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="b5pk3A">Comments</a>
                                      </div>
                                      <div class="modal" data-modal="b5pk3A">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Comments</h4>
                                                                                      <ul>
<li>Acidic formulation may cause irritation</li>
<li>Basaglar<sup>TM</sup> and Semglee<sup>®</sup> are biosimilars to Lantus<sup>®</sup></li>
<li>If a patient is experiencing nocturnal hypoglycemia with a bedtime dose, lower the dose or inject the dose in the morning</li>
<li>Max units/dose: 80 for prefilled pens, 80 for Lantus<sup>®</sup> reusable <span class="tooltip-wrapper"><span class="tooltip-parent">pen</span><span class="tooltip-content">This reflects the maximum amount given for 1 injection, not the maximum amount of insulin that is required. Multiple injections may be required to achieve blood glucose targets.</span></span></li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Long-acting</span>
                    <h6>Glargine (Semglee<sup>®</sup>) </h6>
                    <p><em>100 units/mL</em></p>
<p><strong>Activity profile</strong></p>
<ul>
<li>Onset: 1.5h</li>
<li>Peak: Flat, no discernable peak</li>
<li>Duration: 24h</li>
</ul>
<p><strong>Coverage</strong></p>
<ul>
<li>ODB ✓</li>
<li>NIHB ✓</li>
</ul>
<p><strong>Dosage forms</strong></p>
<ul>
<li>5x3mL prefilled pens</li>
</ul>
<p><strong>Cost for usual dose (50 units/day for 100 days supply; basal alone)*</strong></p>
<ul>
<li>$243</li>
</ul>
<p><strong>Cost for usual dose (25 units/day for 100 days supply; basal + bolus; cost is for basal component)*</strong></p>
<ul>
<li>$126</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="lvg2ce">Comments</a>
                                      </div>
                                      <div class="modal" data-modal="lvg2ce">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Comments</h4>
                                                                                      <ul>
<li>Acidic formulation may cause irritation</li>
<li>Basaglar<sup>TM</sup> and Semglee<sup>®</sup> are biosimilars to Lantus<sup>®</sup></li>
<li>If a patient is experiencing nocturnal hypoglycemia with a bedtime dose, lower the dose or inject the dose in the morning</li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Long-acting</span>
                    <h6>Glargine (Toujeo<sup>®</sup>)</h6>
                    <p><em>300 units/mL </em></p>
<p><strong>Activity profile</strong></p>
<ul>
<li>Onset: 1.5h</li>
<li>Peak: Flat, no discernable peak</li>
<li>Duration: Up to 36h</li>
</ul>
<p><strong>Coverage</strong></p>
<ul>
<li>ODB ✓</li>
<li>NIHB ✓ (1.5mL and 3mL)</li>
</ul>
<p><strong>Dosage forms</strong></p>
<ul>
<li>3&#215;1.5mL or 5&#215;1.5mL prefilled pens</li>
<li>3x3mL prefilled pens</li>
</ul>
<p><strong>Cost for usual dose (50 units/day for 100 days supply; basal alone)*</strong></p>
<ul>
<li>1.5mL prefilled pens: $332</li>
<li>3mL prefilled pens: $332</li>
</ul>
<p><strong>Cost for usual dose (25 units/day for 100 days supply; basal + bolus; cost is for basal component)*</strong></p>
<ul>
<li>1.5mL prefilled pens: $170</li>
<li>3mL prefilled pens: $170</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="aR9Odl">Comments</a>
                                      </div>
                                      <div class="modal" data-modal="aR9Odl">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Comments</h4>
                                                                                      <ul>
<li>Recommend for patients who require &gt;20 units of basal insulin/day, and counsel on change of concentration</li>
<li>NOT bioequivalent to glargine 100 units/mL (longer duration and delayed peak; starting dose when switching can be the same but a higher daily dose may eventually be needed)</li>
<li>If a patient is experiencing nocturnal hypoglycemia with a bedtime dose, lower the dose or inject the dose in the morning</li>
<li>Max units/dose: 80 for 1.5mL prefilled pen, 160 for 3mL prefilled <span class="tooltip-wrapper"><span class="tooltip-parent">pen</span><span class="tooltip-content">This reflects the maximum amount given for 1 injection, not the maximum amount of insulin that is required. Multiple injections may be required to achieve blood glucose targets.</span></span></li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Ultra-long-acting</span>
                    <h6>Icodec (Awiqli<sup>®</sup>)</h6>
                    <p><em>700 units/mL</em></p>
<p><strong>Activity profile</strong></p>
<ul>
<li>2-4 weeks to steady state. At this point it acts as a circulating insulin reservoir.</li>
<li>Glucose-lowering effect covers the full weekly dosing interval.</li>
<li>Peak: 2-4 days</li>
<li>Half-life: ~ 1 week</li>
</ul>
<p><strong>Coverage</strong></p>
<ul>
<li>ODB X</li>
<li>NIHB X</li>
</ul>
<p><strong>Dosage forms</strong></p>
<ul>
<li>1x1mL prefilled pen (sample pack only)</li>
<li>1&#215;1.5mL prefilled pen</li>
<li>1x3mL prefilled pen</li>
</ul>
<p><strong>Cost for usual dose (350 units/week for 100 days supply; basal alone)*</strong></p>
<ul>
<li>1.5mL prefilled pens: $466</li>
<li>3mL prefilled pens: $566</li>
</ul>
<p><strong>Cost for usual dose (175 units/week for 100 days supply; basal + bolus; cost is for basal component)*</strong></p>
<ul>
<li>1.5mL prefilled pens: $285</li>
<li>3mL prefilled pens: $310</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="X2e0hD">Comments</a>
                                      </div>
                                      <div class="modal" data-modal="X2e0hD">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Comments</h4>
                                                                                      <ul>
<li>Once weekly administration; useful for patients with barriers to daily insulin dosing</li>
<li>Can increase the dose by increments of 10 units</li>
<li>Max units/dose: 700</li>
<li><span class="NormalTextRun SCXW63603555 BCX8">Discard </span><span class="NormalTextRun AdvancedProofingIssueV2Themed SCXW63603555 BCX8">12 weeks</span><span class="NormalTextRun SCXW63603555 BCX8"> after first use or after storing at room temperature</span></li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

                      </ul>
        </div>
      </div>
    </div>
</article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading" id="bolus">Prandial (bolus) insulin<sup>1,15,45,53,57,60,61,62</sup></h3>
</div></article>

<article class="block--drug-options ">
<div class="container">
  <h5><span style="font-size: 13.5px;">Scroll (left-right) for details</h5>
          <div class="slider">
        <div class="inner-stage">
          <ul>
            
                <li>
                  <div class="inner">
                    <span class="subhead">Rapid-acting</span>
                    <h6>Aspart (NovoRapid<sup>®</sup>)</h6>
                    <p><em>100 units/mL</em></p>
<p><strong>Activity profile</strong></p>
<ul>
<li>Onset: 9-20 min</li>
<li>Peak: 1-3h</li>
<li>Duration: 3-5h</li>
</ul>
<p><strong>Coverage</strong></p>
<ul>
<li>ODB ✓ (<a href="https://link.cep.health/t2dminhtml53" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Limited use: 628, 642, 643</a> [prefilled pens and cartridges] and <a href="https://link.cep.health/t2dminhtml6" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">389, 390, 642, 643, 644, 646</a> [vial])</li>
<li>NIHB ✓</li>
</ul>
<p><strong>Dosage forms</strong></p>
<ul>
<li>5x3mL cartridges</li>
<li>10mL vial</li>
</ul>
<p><strong>Cost for usual dose (25 units/day for 100 days supply)*</strong></p>
<ul>
<li>3mL cartridges: $121</li>
<li>10mL vial: $92</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="2a7hg1">Comments</a>
                                      </div>
                                      <div class="modal" data-modal="2a7hg1">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Comments</h4>
                                                                                      <ul>
<li>Inject immediately (not more <span dir="ltr">than 5-10 minutes) before or immediately after a meal</span></li>
<li>Max units/dose: 80 for <span dir="ltr">prefilled pen, 60 for reusable <span class="tooltip-wrapper"><span class="tooltip-parent">pen</span><span class="tooltip-content">This reflects the maximum amount given for 1 injection, not the maximum amount of insulin that is required. Multiple injections may be required to achieve blood glucose targets.</span></span></span></li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Rapid-acting</span>
                    <h6>Aspart (Kirsty<sup>®</sup>)</h6>
                    <p><em>100 units/mL</em></p>
<p><strong>Activity profile</strong></p>
<ul>
<li>Onset: 10-20 min</li>
<li>Peak: 1-3h</li>
<li>Duration: 3-5h</li>
</ul>
<p><strong>Coverage</strong></p>
<ul>
<li>ODB ✓</li>
<li>NIHB ✓</li>
</ul>
<p><strong>Dosage forms</strong></p>
<ul>
<li>5x3mL prefilled pens</li>
</ul>
<p><strong>Cost for usual dose (25 units/day for 100 days supply)*</strong></p>
<ul>
<li>$87</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="ccGvGp">Comments</a>
                                      </div>
                                      <div class="modal" data-modal="ccGvGp">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Comments</h4>
                                                                                      <ul>
<li>Inject immediately (not more <span dir="ltr">than 5-10 minutes) before or immediately after a meal</span></li>
<li>Kirsty<sup>®</sup> is biosimilar to NovoRapid<span style="font-size: 1.5rem;"><sup>®</sup></span></li>
<li>Max units/dose: ** 80 for prefilled pen</li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Rapid-acting</span>
                    <h6>Aspart (Trurapi<sup>TM</sup>)</h6>
                    <p><em>100 units/mL</em></p>
<p><strong>Activity profile</strong></p>
<ul>
<li>Onset: 10-20 min</li>
<li>Peak: 1-3h</li>
<li>Duration: 3-5h</li>
</ul>
<p><strong>Coverage</strong></p>
<ul>
<li>ODB ✓ (prefilled pens and cartridges)</li>
<li>ODB X (vial)</li>
<li>NIHB ✓</li>
</ul>
<p><strong>Dosage forms</strong></p>
<ul>
<li>5x3mL prefilled pens</li>
<li>5x3mL cartridges</li>
<li>10mL vial</li>
</ul>
<p><strong>Cost for usual dose (25 units/day for 100 days supply)*</strong></p>
<ul>
<li>3mL prefilled pens: $91</li>
<li>3mL cartridges: $91</li>
<li>10mL vial: $96</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="EqEzL2">Comments</a>
                                      </div>
                                      <div class="modal" data-modal="EqEzL2">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Comments</h4>
                                                                                      <ul>
<li>Inject immediately (not more than 5-10 minutes) before or immediately after a meal</li>
<li>Trurapi® is biosimilar to NovoRapid®</li>
<li>Max units/dose: 80 for prefilled pen, 60 for reusable <span class="tooltip-wrapper"><span class="tooltip-parent">pen</span><span class="tooltip-content">This reflects the maximum amount given for 1 injection, not the maximum amount of insulin that is required. Multiple injections may be required to achieve blood glucose targets.</span></span></li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Rapid-acting</span>
                    <h6>Aspart (Fiasp<sup>®</sup>)</h6>
                    <p><em>100 units/mL</em></p>
<p><em>Not on Ontario drug formulary</em></p>
<p><strong>Activity profile</strong></p>
<ul>
<li>Onset: 4 min</li>
<li>Peak: 0.5-1.5h</li>
<li>Duration: 3-5h</li>
</ul>
<p><strong>Coverage</strong></p>
<ul>
<li>ODB X</li>
<li>NIHB X</li>
</ul>
<p><strong>Dosage forms</strong></p>
<ul>
<li>5x3mL prefilled pens</li>
<li>5x3mL cartridges</li>
<li>10mL vial</li>
</ul>
<p><strong>Cost for usual dose (25 units/day for 100 days supply)*</strong></p>
<ul>
<li>3mL prefilled pens: $136</li>
<li>3mL cartridges: $129</li>
<li>10mL vial: $99</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="JCh08z">Comments</a>
                                      </div>
                                      <div class="modal" data-modal="JCh08z">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Comments</h4>
                                                                                      <ul>
<li>Faster acting insulin</li>
<li>Suggested initial dose for type 2 diabetes in adults is 4 units at one or more meals</li>
<li>Inject at the start of the a meal (up to 2 minutes before meal) or within 20 minutes after starting the meal</li>
<li>Max units/dose: 80 for  prefilled pen, 60 for reusable <span class="tooltip-wrapper"><span class="tooltip-parent">pen</span><span class="tooltip-content">This reflects the maximum amount given for 1 injection, not the maximum amount of insulin that is required. Multiple injections may be required to achieve blood glucose targets.</span></span></li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Rapid-acting</span>
                    <h6>Glulisine (Apidra<sup>®</sup>)</h6>
                    <p><em>100 units/mL</em></p>
<p><strong>Activity profile</strong></p>
<ul>
<li>Onset: 10-15 min</li>
<li>Peak: 1-1.5h</li>
<li>Duration: 3.5-5h</li>
</ul>
<p><strong>Coverage</strong></p>
<ul>
<li>ODB ✓</li>
<li>NIHB ✓</li>
</ul>
<p><strong>Dosage forms</strong></p>
<ul>
<li>5x3mL prefilled pens</li>
<li>5x3mL cartridges</li>
<li>10mL vial</li>
</ul>
<p><strong>Cost for usual dose (25 units/day for 100 days supply)*</strong></p>
<ul>
<li>3mL prefilled pens: $106</li>
<li>3mL cartridges: $105</li>
<li>10mL vial: $82</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="mFIqeJ">Comments</a>
                                      </div>
                                      <div class="modal" data-modal="mFIqeJ">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Comments</h4>
                                                                                      <ul>
<li>Inject within 15 minutes before or within 20 minutes after starting a meal</li>
<li>Max units/dose: 80 for prefilled and reusable <span class="tooltip-wrapper"><span class="tooltip-parent">pens</span><span class="tooltip-content">This reflects the maximum amount given for 1 injection, not the maximum amount of insulin that is required. Multiple injections may be required to achieve blood glucose targets.</span></span></li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Rapid-acting</span>
                    <h6>Lispro (Humalog<sup>®</sup>)</h6>
                    <p><em>100 units/mL</em></p>
<p><strong>Activity profile</strong></p>
<ul>
<li>Onset: 10-15 min</li>
<li>Peak: 0.75-2.5h</li>
<li>Duration: 3.5-4.75h</li>
</ul>
<p><strong>Coverage</strong></p>
<ul>
<li>ODB ✓(<a href="https://link.cep.health/t2dminhtml7" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Limited use: 599, 642, 643</a><sup> [</sup>prefilled pens and cartridges] and  <a href="https://link.cep.health/t2dminhtml7" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">599, 642, 643, 646</a><sup> </sup>[vial])</li>
<li>NIHB ✓</li>
</ul>
<p><strong>Dosage forms</strong></p>
<ul>
<li>5x3mL prefilled pens</li>
<li>5x3mL cartridges</li>
<li>10mL vial</li>
</ul>
<p><strong>Cost for usual dose (25 units/day for 100 days supply)*</strong></p>
<ul>
<li>3mL prefilled pens: $129</li>
<li>3mL cartridges: $128</li>
<li>10mL vial: $100</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="BPgP43">Comments</a>
                                      </div>
                                      <div class="modal" data-modal="BPgP43">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Comments</h4>
                                                                                      <ul>
<li>Inject within 15 minutes before a meal or within 20 minutes after starting the meal</li>
<li>Admelog<sup>®</sup> is biosimilar to Humalog<sup>®</sup></li>
<li>Max units/dose: 60 for Humalog<sup>®</sup> prefilled and reusable <span class="tooltip-wrapper"><span class="tooltip-parent">pens</span><span class="tooltip-content">This reflects the maximum amount given for 1 injection, not the maximum amount of insulin that is required. Multiple injections may be required to achieve blood glucose targets.</span></span></li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Rapid-acting</span>
                    <h6>Lispro (Admelog<sup>®</sup>)</h6>
                    <p><em>100 units/mL</em></p>
<p><strong>Activity profile</strong></p>
<ul>
<li>Onset: 10-15 min</li>
<li>Peak: 0.75-2.5h</li>
<li>Duration: 3.5-4.75h</li>
</ul>
<p><strong>Coverage</strong></p>
<ul>
<li>ODB ✓</li>
<li>NIHB ✓</li>
</ul>
<p><strong>Dosage forms</strong></p>
<ul>
<li>5x3mL prefilled pens</li>
<li>5x3mL cartridges</li>
<li>10mL vial</li>
</ul>
<p><strong>Cost for usual dose (25 units/day for 100 days supply)*</strong></p>
<ul>
<li>3mL prefilled pens: $91</li>
<li>3mL cartridges: $91</li>
<li>10mL vial: $71</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="7y3fTX">Comments</a>
                                      </div>
                                      <div class="modal" data-modal="7y3fTX">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Comments</h4>
                                                                                      <ul>
<li>Inject within 15 minutes before a meal or within 20 minutes after starting the meal</li>
<li>Admelog<sup>®</sup> is biosimi-lar to Humalog<sup>®</sup></li>
<li>Max units/dose: 80 for Admelog<sup>®</sup> prefilled and reusable <span class="tooltip-wrapper"><span class="tooltip-parent">pens</span><span class="tooltip-content">This reflects the maximum amount given for 1 injection, not the maximum amount of insulin that is required. Multiple injections may be required to achieve blood glucose targets.</span></span></li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Rapid-acting</span>
                    <h6>Lispro (Humalog<sup>®</sup>)</h6>
                    <p><em>200 units/mL</em></p>
<p><strong>Activity profile</strong></p>
<ul>
<li>Onset: 10-15 min</li>
<li>Peak: 0.75-2.5h</li>
<li>Duration: 3.5-4.75h</li>
</ul>
<p><strong>Coverage</strong></p>
<ul>
<li>ODB ✓</li>
<li>NIHB ✓</li>
</ul>
<p><strong>Dosage forms</strong></p>
<ul>
<li>5x3mL prefilled pens</li>
</ul>
<p><strong>Cost for usual dose (25 units/day for 100 days supply)*</strong></p>
<ul>
<li>$120</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="ToSw70">Comments</a>
                                      </div>
                                      <div class="modal" data-modal="ToSw70">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Comments</h4>
                                                                                      <ul>
<li>Higher concentration requires smaller volume</li>
<li>Recommend for patients who require &gt;20 units of prandial (bolus) insulin/day, and counsel on change of concentration</li>
<li>Max units/dose: 60 for prefilled <span class="tooltip-wrapper"><span class="tooltip-parent">pen</span><span class="tooltip-content">This reflects the maximum amount given for 1 injection, not the maximum amount of insulin that is required. Multiple injections may be required to achieve blood glucose targets.</span></span></li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Short-acting</span>
                    <h6>Regular insulin (Humulin<sup>®</sup> R) </h6>
                    <p><em>100 units/mL</em></p>
<p><strong>Activity profile</strong></p>
<ul>
<li>Onset: 30-60 min</li>
<li>Peak: 2-4h</li>
<li>Duration: 5-8h</li>
</ul>
<p><strong>Coverage</strong></p>
<ul>
<li>ODB ✓ (prefilled pen and cartirdge)</li>
<li>ODB X (vial)</li>
<li>NIHB ✓</li>
</ul>
<p><strong>Dosage forms</strong></p>
<ul>
<li>5x3mL prefilled pen</li>
<li>5x3mL cartridges</li>
<li>10mL vial</li>
</ul>
<p><strong>Cost for usual dose (25 units/day for 100 days supply)*</strong></p>
<ul>
<li>3mL prefilled pen: $107</li>
<li>3mL cartridges: $107</li>
<li>10mL vial: $84</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="HpGVL8">Comments</a>
                                      </div>
                                      <div class="modal" data-modal="HpGVL8">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Comments</h4>
                                                                                      <ul>
<li>Inject 15-30 minutes before meals</li>
<li>Max units/dose: 60 for Humulin R<sup>®</sup> resuable <span class="tooltip-wrapper"><span class="tooltip-parent">pen</span><span class="tooltip-content">This reflects the maximum amount given for 1 injection, not the maximum amount of insulin that is required. Multiple injections may be required to achieve blood glucose targets.</span></span></li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Short-acting</span>
                    <h6>Regular insulin (Novolin<sup>®</sup>ge Toronto) </h6>
                    <p><em>100 units/mL</em></p>
<p><strong>Activity profile</strong></p>
<ul>
<li>Onset: 30-60 min</li>
<li>Peak: 2-4h</li>
<li>Duration: 5-8h</li>
</ul>
<p><strong>Coverage</strong></p>
<ul>
<li>ODB ✓ (prefilled pen and cartirdge)</li>
<li>ODB X (vial)</li>
<li>NIHB ✓</li>
</ul>
<p><strong>Dosage forms</strong></p>
<ul>
<li>5x3mL cartridges</li>
<li>10mL vial</li>
</ul>
<p><strong>Cost for usual dose (25 units/day for 100 days supply)*</strong></p>
<ul>
<li>3mL cartridges: $96</li>
<li>10mL vial: $76</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="3cvTRk">Comments</a>
                                      </div>
                                      <div class="modal" data-modal="3cvTRk">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Comments</h4>
                                                                                      <ul>
<li>Inject 15-30 minutes before meal</li>
<li>Max units/dose: 60 for Novolin<sup>®</sup>ge Toronto resuable <span class="tooltip-wrapper"><span class="tooltip-parent">pen</span><span class="tooltip-content">This reflects the maximum amount given for 1 injection, not the maximum amount of insulin that is required. Multiple injections may be required to achieve blood glucose targets.</span></span></li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Short-acting</span>
                    <h6>Regular insulin (Entuzity<sup>®</sup>)</h6>
                    <p><em>500 units/mL</em></p>
<p><em>Not on Ontario drug formulary</em></p>
<p><strong>Activity profile</strong></p>
<ul>
<li>Onset: 3-58 min</li>
<li>Peak: 0.5-8h</li>
<li>Duration: 17-24h</li>
</ul>
<p><strong>Coverage</strong></p>
<ul>
<li>ODB ✓</li>
<li>NIHB ✓</li>
</ul>
<p><strong>Dosage forms</strong></p>
<ul>
<li>2x3mL prefilled pens</li>
</ul>
<p><strong>Cost for usual dose </strong><strong>(25 units/day for 100 days supply)*</strong></p>
<ul>
<li>$95</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="YdKlu5">Comments</a>
                                      </div>
                                      <div class="modal" data-modal="YdKlu5">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Comments</h4>
                                                                                      <ul>
<li>Inject 15-30 minutes before meals</li>
<li>Entuzity<sup>®</sup> should be reserved for patients who require &gt; 200 units/day and delivers  insulin in 5-unit increments</li>
<li>Entuzity<sup>®</sup> has a unique pharmacokinetic profile with an onset similar to regular insulin and a duration similar to some basal/premixed insulins</li>
<li>Max units/dose: 300 for Entuzity<sup>®</sup> prefilled <span class="tooltip-wrapper"><span class="tooltip-parent">pen</span><span class="tooltip-content">This reflects the maximum amount given for 1 injection, not the maximum amount of insulin that is required. Multiple injections may be required to achieve blood glucose targets.</span></span></li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

                      </ul>
        </div>
      </div>
    </div>
</article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading" id="premixedoptions">Premixed insulin and GLP1-RA + insulin combinations<sup>15,45,53,54,57</sup></h3>
</div></article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p>The choice of premixed insulin will depend on the patient’s dosing requirements for basal and prandial (bolus) insulin and which type of prandial insulin is preferred by the patient and provider. Refer to individual components above for onset, peak and duration.</p>
</div></article>

<article class="block--drug-options ">
<div class="container">
  <h5><span style="font-size: 13.5px;">Scroll (left-right) for details</h5>
          <div class="slider">
        <div class="inner-stage">
          <ul>
            
                <li>
                  <div class="inner">
                    <span class="subhead">Short-acting + intermediate-acting</span>
                    <h6>Premixed regular/NPH (Humulin<sup>®</sup> 30/70)</h6>
                    <p><em>100 units/mL</em></p>
<p><strong>Coverage</strong></p>
<ul>
<li>ODB ✓</li>
<li>NIHB ✓</li>
</ul>
<p><strong>Dosage forms</strong></p>
<ul>
<li>5x3mL cartridges</li>
<li>10mL vial</li>
</ul>
<p><strong>Cost for usual dose (50 units/day for 100 days supply)*</strong></p>
<ul>
<li>3mL cartridges: $197</li>
<li>10mL vial: $150</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="bmtCi6">Comments</a>
                                      </div>
                                      <div class="modal" data-modal="bmtCi6">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Comments</h4>
                                                                                      <ul>
<li>Contain both short-acting regular prandial (bolus) insulin and intermediate-acting NPH basal insulin</li>
<li>The numbers in the product name (30/70) refer to the percentage of each type of insulin contained in the product (e.g., Novolin ge 30/70<sup>®</sup> contains 30% regular insulin and 70% NPH insulin)</li>
<li>Inject bid 30 minutes before eating</li>
<li><span dir="ltr">Max units/dose: 60 for reusable </span><span class="tooltip-wrapper"><span class="tooltip-parent">pen</span><span class="tooltip-content">This reflects the maximum amount given for 1 injection, not the maximum amount of insulin that is required. Multiple injections may be required to achieve blood glucose targets.</span></span></li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Short-acting + intermediate-acting</span>
                    <h6>Premixed regular/NPH (Novolin<sup>®</sup>ge 30/70)</h6>
                    <p><em>100 units/mL</em></p>
<p><strong>Coverage</strong></p>
<ul>
<li>ODB ✓</li>
<li>NIHB ✓</li>
</ul>
<p><strong>Dosage forms</strong></p>
<ul>
<li>5x3mL cartridges</li>
<li>10mL vial</li>
</ul>
<p><strong>Cost for usual dose (50 units/day for 100 days supply)*</strong></p>
<ul>
<li>5x3mL cartridges: $173</li>
<li>10mL vial: $140</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="ucLSIF">Comments</a>
                                      </div>
                                      <div class="modal" data-modal="ucLSIF">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Comments</h4>
                                                                                      <ul>
<li>Contain both short-acting regular prandial (bolus) insulin and intermediate-acting NPH basal insulin</li>
<li>The numbers in the product name (30/70) refer to the percentage of each type of insulin contained in the product (e.g., Novolin ge 30/70<sup>®</sup> contains 30% regular insulin and 70% NPH insulin)</li>
<li>Inject bid 30 minutes before eating</li>
<li><span dir="ltr">Max units/dose: 60 for reusable </span><span class="tooltip-wrapper"><span class="tooltip-parent">pen</span><span class="tooltip-content">This reflects the maximum amount given for 1 injection, not the maximum amount of insulin that is required. Multiple injections may be required to achieve blood glucose targets.</span></span></li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Rapid-acting + intermediate-acting</span>
                    <h6>Aspart/aspart protamine suspension (Novomix<sup>®</sup> 30)</h6>
                    <p><em>100 units/mL</em></p>
<p><strong>Coverage</strong></p>
<ul>
<li>ODB ✓</li>
<li>NIHB ✓</li>
</ul>
<p><strong>Dosage forms</strong></p>
<ul>
<li>5x3mL cartridges</li>
</ul>
<p><strong>Cost for usual dose (50 units/day for 100 days supply)*</strong></p>
<ul>
<li>$203</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="DQR1wF">Comments</a>
                                      </div>
                                      <div class="modal" data-modal="DQR1wF">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Comments</h4>
                                                                                      <ul>
<li>Contains 30% rapid-acting prandial (bolus) insulin aspart and 70% intermediate-acting insulin aspart protamine crystals</li>
<li><span dir="ltr">Inject within 10 minutes before eating</span></li>
<li><span dir="ltr">Max units/dose: </span><span class="tooltip-wrapper"><span class="tooltip-parent">60</span><span class="tooltip-content">This reflects the maximum amount given for 1 injection, not the maximum amount of insulin that is required. Multiple injections may be required to achieve blood glucose targets.</span></span></li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Rapid-acting + intermediate-acting</span>
                    <h6>Lispro/lispro protamine suspension (Humalog<sup>®</sup> Mix25)</h6>
                    <p><em>100 units/mL</em></p>
<p><strong>Coverage</strong></p>
<ul>
<li>ODB ✓</li>
<li>NIHB ✓</li>
</ul>
<p><strong>Dosage forms</strong></p>
<ul>
<li>5x3mL prefilled pens</li>
<li>5x3mL cartridges</li>
</ul>
<p><strong>Cost for usual dose (50 units/day for 100 days supply)*</strong></p>
<ul>
<li>3mL prefilled pens: $205</li>
<li>3mL cartridges: $206</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="4I1wmt">Comments</a>
                                      </div>
                                      <div class="modal" data-modal="4I1wmt">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Comments</h4>
                                                                                      <ul>
<li>Contains a mix of rapid-acting prandial (bolus) insulin lispro (either 25% to 50%) and intermediate acting insulin lispro protamine suspension (either 75% or 50%)</li>
<li><span dir="ltr">Inject within 10 minutes before </span><span dir="ltr">eating</span></li>
<li><span dir="ltr">Max units/dose: 60 for prefilled </span><span dir="ltr">and reusable </span><span class="tooltip-wrapper"><span class="tooltip-parent">pen</span><span class="tooltip-content">This reflects the maximum amount given for 1 injection, not the maximum amount of insulin that is required. Multiple injections may be required to achieve blood glucose targets.</span></span></li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Rapid-acting + intermediate-acting</span>
                    <h6>Lispro/lispro protamine suspension (Humalog<sup>®</sup> Mix50)</h6>
                    <p><em>100 units/mL</em></p>
<p><strong>Coverage</strong></p>
<ul>
<li>ODB ✓</li>
<li>NIHB ✓</li>
</ul>
<p><strong>Dosage forms</strong></p>
<ul>
<li>5x3mL prefilled pens</li>
<li>5x3mL cartridges</li>
</ul>
<p><strong>Cost for usual dose (50 units/day for 100 days supply)*</strong></p>
<ul>
<li>3mL prefilled pens: $201</li>
<li>3mL cartridges: $203</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="XRdYFW">Comments</a>
                                      </div>
                                      <div class="modal" data-modal="XRdYFW">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Comments</h4>
                                                                                      <ul>
<li>Contains a mix of rapid-acting prandial (bolus) insulin lispro (either 25% to 50%) and intermediate acting insulin lispro protamine suspension (either 75% or 50%)</li>
<li><span dir="ltr">Inject within 10 minutes before </span><span dir="ltr">eating</span></li>
<li><span dir="ltr">Max units/dose: 60 for prefilled </span><span dir="ltr">and reusable </span><span class="tooltip-wrapper"><span class="tooltip-parent">pen</span><span class="tooltip-content">This reflects the maximum amount given for 1 injection, not the maximum amount of insulin that is required. Multiple injections may be required to achieve blood glucose targets.</span></span></li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">GLP1-RA + insulin combinations (not premixed insulins)</span>
                    <h6>Degludec/liraglutide (Xultophy<sup>®</sup>)</h6>
                    <p><em>100 units/mL</em></p>
<p><em>Not on Ontario drug formulary</em></p>
<p><strong>Coverage</strong></p>
<ul>
<li>ODB X</li>
<li>NIHB X</li>
</ul>
<p><strong>Dosage forms</strong></p>
<ul>
<li>5x3mL cartridges</li>
</ul>
<p><strong>Cost for usual dose (50 units/day for 100 days supply)*</strong></p>
<ul>
<li>$1,065</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="d0loI0">Comments</a>
                                      </div>
                                      <div class="modal" data-modal="d0loI0">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Comments</h4>
                                                                                      <ul>
<li>Contains a mix of long-acting basal insulin degludec and GLP1-RA liraglutide</li>
<li>Inject 16 units/0.58mg – 50 units/1.8mg SC daily</li>
<li>Administer at any time of the day (but same time every day) independent of meals</li>
<li><span dir="ltr">Max: 50 units insulin daily</span></li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">GLP1-RA + insulin combinations (not premixed insulins)</span>
                    <h6>Glargine/lixisenatide  (Soliqua<sup>®</sup>)</h6>
                    <p><em>100 units/mL</em></p>
<p><strong>Coverage</strong></p>
<ul>
<li>ODB ✓</li>
<li>NIHB ✓</li>
</ul>
<p><strong>Dosage forms</strong></p>
<ul>
<li>5x3mL cartridges</li>
</ul>
<p><strong>Cost for usual dose (50 units/day for 100 days supply)*</strong></p>
<ul>
<li>$624</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="HMGvWB">Comments</a>
                                      </div>
                                      <div class="modal" data-modal="HMGvWB">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Comments</h4>
                                                                                      <ul>
<li>Contains a mix of long-acting basal insulin glargine 100 units/mL and GLP1-RA lixisenatide</li>
<li>Inject 15 units/5μg – 60 units/20μg SC daily</li>
<li>Administer within 1 hour before the first meal of the day</li>
<li>Max: 60 units insulin daily</li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

                      </ul>
        </div>
      </div>
    </div>
</article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p style="font-size:12px">* Prices reflect the cost to the consumer and include a markup and dispensing fee (the cost per dosage form and the 100-day cost both include one dispensing fee and reflect the usual pharmacy practice of dispensing a full box or vial; e.g., 5x3mL pens). The cost for a usual dose assumes a 100 kg patient. The price for vials does not include the cost of syringes.<br>✓ = general benefit, ? = not a benefit, <strong>bid</strong> = twice daily, <strong>h</strong> = hour, <strong>kg</strong> = kilogram, <strong>max</strong> = maximum, <strong>μg</strong> = microgram, <strong>mg</strong> = milligram, <strong>mL</strong> = milliliter, <strong>NIHB</strong> = non-insured health benefits for First Nations and Inuit, <strong>NPH</strong> = neutral protamine Hagedorn, <strong>ODB</strong> = Ontario Drug Benefit, <strong>SC</strong> = subcutaneous</p>
</div></article>						</div>
					</div>
				</section>
							<section class="main-section" id="initiating-and-titrating-insulin" tabindex="-1">
					<div class="head">
						<div class="container">
							<h2 class="main-heading">
								Initiating and titrating insulin								
							</h2>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
						</div>
					</div>
					<div class="body">
						<div class="container">
							<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading">Practical tips for discussing insulin initiation with patients<sup>57</sup></h3>
</div></article>

<article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Checkmark-Large-2.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <ul>
<li>Start the insulin discussion early (e.g., at diagnosis and regular follow-up appointments)</li>
<li>Ensure patients understand that insulin is not a punishment or indication of treatment failure, and that many patients end up on insulin later in life</li>
<li>Consider patient values regarding the benefits/harms of adding insulin relative to the intensity of glycemic control (e.g., some patients may opt for moderate control without insulin)</li>
<li>Provide information on the benefits of insulin therapy (e.g., lower blood glucose, no gastrointestinal upset, reduces nocturnal urination secondary to hyperglycemia)</li>
<li>Understand the patient’s barriers or concerns about starting insulin</li>
<li>Consider framing starting insulin as a “trial”, with a set duration (e.g., 1 month), with a plan to discuss and adjust as needed</li>
<li>To increase their confidence before starting injection(s), give the patient time to try different insulin pens and needles</li>
</ul>
          </div>
        </div>

      </div>
</article>

<article class="block--background  core-block" data-block-name="cep/background"><div class="container">
<div class="wp-block-cep-background is-style-blue-background"><article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/talking-points.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <h6 id="block-ea7c8c19-187d-46fc-9256-ca1414a5dd08" class="block-editor-rich-text__editable block-editor-block-list__block wp-block is-selected rich-text" tabindex="0" role="group" contenteditable="true" aria-multiline="true" aria-label="Block: Heading" data-block="ea7c8c19-187d-46fc-9256-ca1414a5dd08" data-type="core/heading" data-title="Heading">Talking points<sup>57</sup></h6>
<ul>
<li>“For most people living with diabetes, insulin is required at some point in their life as part of their management plan.”</li>
<li>“Since you are not feeling well now, adding insulin may help you feel better sooner.” (Offer the patient examples of their symptoms, e.g., blurred vision, fatigue, low energy. increased urination).”</li>
<li>“The insulin needle injection hurts less than a fingerprick when checking blood glucose.”</li>
<li>“Would you be open to trying insulin therapy for 1 month to see how it works for you?”</li>
</ul>
          </div>
        </div>

      </div>
</article></div>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading">Insulin initiation checklist</h3>
</div></article>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h5 class="wp-block-heading"><strong>Counsel patients on</strong>:</h5>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Insulin injection frequency and timing</li>



<li>Proper and safe insulin injection techniques, pen needle use and insulin storage<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Consider connecting the patient to a qualified person/program to provide this counselling (e.g., Certified Diabetes Educator, Diabetes Education Program/Centre or collaborative support [registered nurse, nurse practitioner, pharmacist, dietitian] in the office or community). See <a href="https://link.cep.health/t2dminhtml8" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Local services for patients living with type 2 diabetes</a></li>
</ul>
</div></article></li>



<li>Hypoglycemia prevention and treatment (see <a href="https://tools.cep.health/tool/type-2-diabetes-insulin-therapy/#managing-hypoglycemia" data-wpel-link="internal">Managing hypoglycemia</a>)</li>



<li>Frequency of self-monitoring of blood glucose (See <a href="https://link.cep.health/t2dminhtml9" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Self monitoring blood glucose frequency and pattern tool</a>)<sup>63</sup></li>



<li>Options for blood glucose self-monitoring devices/systems (e.g., blood glucose meter, flash glucose monitoring system, continuous glucose monitoring system)</li>



<li>Changes to current non-insulin pharmacotherapy dosing, if applicable (see <a href="#initiationprocess">Insulin initiation and titration process</a>)</li>
</ul>
</div></article></div>



<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><article class="block--table ">
<div class="container">
  <div class="table  inner-border-grey blue">

                    <header>
                <h6><b>Storing insulin<sup>64,65</sup></b></h6>
            </header>
        
                    <div class="rows">

                                    <div class="row">

                                                    <div class="cols">
                        
                                
                                                                            <div class="col 1" style="flex-basis:33%;">
                                            <p><strong> Unopened insulin</strong></p>
<ul>
<li>Should be stored in the fridge between 2ºC and 8ºC</li>
<li>Is safe to use until the expiration date</li>
</ul>
<p><strong>In-use insulin</strong></p>
<ul>
<li>Should be stored at room temperature, avoiding contact  with direct sunlight</li>
<li>Is generally good for up to 28 days (detemir and glargine 300 units/mL are safe at room temperature for 42 days, <span dir="ltr">degludec is safe at </span><span dir="ltr">room temperature for 56 days, and icodec is safe at room temperature for 12 weeks</span>) &#8211; counsel patient  to write the first date of use on the label</li>
</ul>
<p><strong>When to discard</strong></p>
<ul>
<li>If it has been frozen</li>
<li>If kept out of the fridge for longer than the specified period</li>
<li>If exposed to temperatures greater than 30ºC</li>
<li>If it has expired</li>
</ul>
                                        </div>
                                    
                                                            </div>
                        
                    </div>
                
            </div>
        
        
    </div>
</div>
</article></div>
</div>


<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading" id="safeinjection"><strong>Safe insulin injection techniques and pen needle use<sup>66</sup>&nbsp;</strong></h3>
</div></article>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow" style="flex-basis:50%"><article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Injection sites and rotation (proper injection technique can significantly improve A1C and reduce erratic insulin effects and hypoglycemia)<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Divide injection area into zones, use 1 zone per week and move clockwise, spacing out each injection within any zone by 1-2 cm</li>



<li>Avoid intramuscular injection<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Abdomen, thighs and buttocks as the preferred self-injection areas</li>



<li>Avoid the arms</li>
</ul>
</div></article></li>



<li>Avoid injecting within 2-3 cm of the umbilicus</li>



<li>Avoid injecting in altered skin (e.g., skin with surgical scars, stretch marks, lipohypertrophy, tattoos, moles, skin conditions)</li>
</ul>
</div></article></li>



<li>Pen needles<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Insulin should be brought to room temperature before injecting</li>



<li>Inject pen needles at a 90˚ angle</li>



<li>Avoid reusing pen needles or syringes</li>



<li>Use pen needle sized 4-6 mm for all patients regardless of body mass index (4 mm pen needles provide the equivalent A1C control as both as 8 mm and 12 mm pen needles in people with obesity who are taking large doses of insulin)<sup>67</sup></li>
</ul>
</div></article></li>



<li>See <a href="https://link.cep.health/t2dminhtml10" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">FIT technique plus</a> for a series of patient educational tools on best practice injection technique and pen needle use</li>
</ul>
</div></article></div>



<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow" style="flex-basis:50%"><article class="block--background  core-block" data-block-name="cep/background"><div class="container">
<div class="wp-block-cep-background is-style-blue-background"><article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p class="has-text-align-center"><strong><strong>Injection site rotation</strong></strong></p>
</div></article>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow" style="flex-basis:50%"><article class="block--image  core-block" data-block-name="core/image"><div class="container">
<figure class="wp-block-image size-large is-resized is-style-default"><img loading="lazy" decoding="async" width="368" height="369" src="https://tools.cep.health/wp-content/uploads/2021/03/Screen-Shot-2021-03-25-at-2.40.24-PM.png" alt="" class="wp-image-28538" style="width:174px;height:174px"/></figure>
</div></article></div>



<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow" style="flex-basis:50%"><article class="block--image  core-block" data-block-name="core/image"><div class="container">
<figure class="wp-block-image size-large is-resized is-style-default"><img loading="lazy" decoding="async" width="359" height="360" src="https://tools.cep.health/wp-content/uploads/2021/03/Screen-Shot-2021-03-25-at-2.40.36-PM.png" alt="" class="wp-image-28539" style="width:174px;height:174px"/></figure>
</div></article></div>
</div>


<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p class="has-text-align-center"><strong>Pen needle wear after use</strong></p>
</div></article>

<article class="block--image  core-block" data-block-name="core/image"><div class="container">
<figure class="wp-block-image aligncenter size-large is-style-default"><img loading="lazy" decoding="async" width="300" height="106" src="https://tools.cep.health/wp-content/uploads/2021/05/penneedle.png" alt="" class="wp-image-32200"/></figure>
</div></article></div>
</div></article></div>
</div>


<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading">Insulin&nbsp;initiation and titration</h3>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h5 class="wp-block-heading">Support patients to self-monitor</h5>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Fasting blood glucose and 2-hour post-prandial blood glucose (See <a href="https://link.cep.health/t2dminhtml9" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Self-monitoring blood glucose frequency and pattern tool</a> for individualized timing<sup>63</sup>)</li>



<li>Blood glucose levels in the middle of the night (1-2 times/month) to determine if they are experiencing nocturnal hypoglycemia<sup>57</sup></li>



<li>Blood glucose at least 2 times/day to safely titrate premixed insulin<sup>14</sup></li>
</ul>
</div></article>

<article class="block--table ">
<div class="container">
  <div class="table  inner-border-blue blue">

                    <header>
                <h5>Targets<sup>2,14</sup></h5>
<p>See <a href="https://link.cep.health/t2dminhtml11" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Insulin prescription</a> for examples<sup>68</sup></p>
            </header>
        
                    <div class="rows">

                                    <div class="row">

                                                    <div class="cols">
                        
                                
                                                                            <div class="col 1" style="flex-basis:33%;">
                                            <h6><strong>Fasting blood glucose</strong></h6>
<ul>
<li>Usual: 4.0-7.0 mmol/L (if A1C is not at target, consider a target of 4.0-5.5 mmol/L, balanced against the risk of hypoglycemia)</li>
<li>Functionally dependent/frail:* targets may be relaxed</li>
</ul>
                                        </div>
                                    
                                
                                                                            <div class="col 2" style="flex-basis:33%;">
                                            <h6><strong>Pre-prandial blood glucose</strong></h6>
<ul>
<li>Usual: 4.0-7.0 mmol/L</li>
<li>Functionally dependent:* 5.0-8.0 mmol/L</li>
<li>Frail/dementia:* 6.0-9.0 mmol/L</li>
</ul>
                                        </div>
                                    
                                
                                                                            <div class="col 3" style="flex-basis:33%;">
                                            <h6><strong>Post-prandial blood glucose</strong></h6>
<ul>
<li>Usual: 5.0-10.0 mmol/L</li>
<li>Functionally dependent:* &lt; 12.0 mmol/L</li>
<li>Frail/dementia:* &lt; 14.0 mmol/L</li>
</ul>
                                        </div>
                                    
                                                            </div>
                        
                    </div>
                
            </div>
        
                    <footer>
                <p><em>*Functionally dependent patients have a <a href="https://link.cep.health/t2dminhmtl80" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Clinical Frailty Scale<sup>11</sup></a><sup> </sup>score of 4-5 on a 9-point scale. Patients with frailty have a <a href="https://link.cep.health/t2dminhmtl80" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Clinical Frailty Scale<sup>11</sup></a> score of 6-8 on a 9-point scale.</em></p>
            </footer>
        
    </div>
</div>
</article>

<article class="block--faq "><div class="container">
    <div class="faq-title-wrapper">
        <div class="faq-icon-wrapper">
            <img decoding="async" class="faq-icon" src="https://tools.cep.health/wp-content/uploads/2020/05/info-icon.svg" alt="" />
        </div>
        <h3 class="faq-title"><h5 id="initiationprocess">Insulin initiation and titration process</h5></h3>
    </div>
            <div class="questions">
                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Basal insulin<sup>1,2,14,15,28,57,68-70,103,104</sup></h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <p><img decoding="async" src="https://tools.cep.health/wp-content/uploads/2023/06/Traffice-light-1.png" alt="basil insulin" /></p>
<h6>Initiating and titrating flow chart</h6>
<p><img loading="lazy" decoding="async" class="" src="https://tools.cep.health/wp-content/uploads/2024/07/CEP_InsulinTherapy_graphics_Jul222024.png" alt="Initiating and titrating flow chart" width="870" height="940" /></p>
                        </div>
                    </div>
                                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Prandial (bolus)<sup>1,2,14,15,28,57,68,71</sup></h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <p><img decoding="async" src="https://tools.cep.health/wp-content/uploads/2023/06/Traffic-light-2.png" alt="prandial (bolus) traffic light" /></p>
<h6>Initiating and titrating flow chart</h6>
<p><img loading="lazy" decoding="async" class="" src="https://link.cep.health/t2dminhtml67" alt="prandial initiating and titrating flow chart" width="763" height="799" /></p>
<p><em>*As effective as starting prandial insulin at all meals, but with lower risk of hypoglycemia and greater patient satisfaction at 1 year<sup>57</sup></em></p>
                        </div>
                    </div>
                                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Premixed insulin and GLP1-RA+insulin<sup>2,14,15,28,57,68,70-72</sup></h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <p><img decoding="async" src="https://tools.cep.health/wp-content/uploads/2023/06/Traffic-light-3.png" alt="premixed insulin and GLP1-RA-insulin traffic light" /></p>
<h6>Initiating and titrating flow chart</h6>
<p><img loading="lazy" decoding="async" class="" src="https://link.cep.health/t2dminhmtl71" alt="Premixed insulin initiating and titrating flow chart" width="767" height="606" /></p>
                        </div>
                    </div>
                                    </div>
    </div></article>						</div>
					</div>
				</section>
							<section class="main-section" id="switching-insulin" tabindex="-1">
					<div class="head">
						<div class="container">
							<h2 class="main-heading">
								Switching insulin								
							</h2>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
						</div>
					</div>
					<div class="body">
						<div class="container">
							<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading">When to switch insulin<sup>57</sup></h3>
</div></article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p>Consider switching to insulin if patient presents the following:</p>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Hypoglycemia</li>



<li>Weight gain</li>



<li>Hyperglycemia </li>



<li>Higher or more concentrated dose required</li>



<li>Cost and coverage concerns, if raised by the patient</li>



<li>Patient convenience </li>
</ul>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading">How to switch insulin<sup>15,28</sup></h3>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Confirm current insulin dose, including agent, concentration and dosage form used</li>



<li>Switching insulin often involves switching insulin pen devices</li>



<li>Counsel patients to temporarily increase the frequency of blood glucose monitoring during switch</li>



<li>Two approaches to switch insulin (20% dose reduction or &#8216;unit-to-unit&#8217;), with a third approach to switch from daily to weekly insulin</li>
</ul>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h5 class="wp-block-heading">Switch insulin using a 20% dose reduction<sup>15,28</sup></h5>
</div></article>

<article class="block--image  core-block" data-block-name="core/image"><div class="container">
<figure class="wp-block-image size-large"><img decoding="async" src="https://tools.cep.health/wp-content/uploads/2023/08/CEP_InsulinTherapy_Aug9.png" alt=""/></figure>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h5 class="wp-block-heading">Switch insulin &#8216;unit-to-unit&#8217;<sup>11,22,102,103</sup></h5>
</div></article>

<article class="block--image  core-block" data-block-name="core/image"><div class="container">
<figure class="wp-block-image size-large"><img decoding="async" src="https://tools.cep.health/wp-content/uploads/2023/06/Switching-insulin-2.png" alt=""/></figure>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h5 class="wp-block-heading">Switch from daily to weekly insulin (basal only)<sup>103,104</sup></h5>
</div></article>

<article class="block--table ">
<div class="container">
  <div class="table  inner-border-grey blue">

                    <header>
                <h6>Initial dosing when switching from daily basal insulin*</h6>
            </header>
        
                    <div class="rows">

                                    <div class="row">

                                                    <div class="cols">
                        
                                
                                                                            <div class="col 1" style="flex-basis:15%;">
                                            <p><strong>Week 1**</strong></p>
                                        </div>
                                    
                                
                                                                            <div class="col 2" style="flex-basis:85%;">
                                            <p>7x daily basal dose.</p>
<p>Consider 10.5x daily basal dose (first dose only)- the risks of hypoglycemic events should be weighed against the risks of temporary worsening glycemic control (hyperglycemia).</p>
                                        </div>
                                    
                                                            </div>
                        
                    </div>
                                    <div class="row">

                                                    <div class="cols">
                        
                                
                                                                            <div class="col 1" style="flex-basis:15%;">
                                            <p><strong>Week 2</strong></p>
                                        </div>
                                    
                                
                                                                            <div class="col 2" style="flex-basis:85%;">
                                            <p>7x daily basal dose + titration as needed (see <a href="#initiationprocess">Insulin initiation and titration process</a>).</p>
<p>Clinicians may decide to titrate less aggressively for patients at greater risk of hypoglycemia.</p>
<p><strong>If week 1 dose was 10.5x daily basal dose, decrease to 7x daily basal dose for week 2.</strong></p>
                                        </div>
                                    
                                                            </div>
                        
                    </div>
                                    <div class="row">

                                                    <div class="cols">
                        
                                
                                                                            <div class="col 1" style="flex-basis:15%;">
                                            <p><strong>Week 3 onward</strong></p>
                                        </div>
                                    
                                
                                                                            <div class="col 2" style="flex-basis:85%;">
                                            <p>Ongoing titration as needed (see <a href="#initiationprocess">Insulin initiation and titration process</a>).</p>
                                        </div>
                                    
                                                            </div>
                        
                    </div>
                
            </div>
        
                    <footer>
                <p><em>*Rounded to the nearest 10 units.</em><br />
<em>**First weekly dose should be taken the day following the last dose of daily basal insulin.</em></p>
            </footer>
        
    </div>
</div>
</article>						</div>
					</div>
				</section>
							<section class="main-section" id="managing-hypoglycemia" tabindex="-1">
					<div class="head">
						<div class="container">
							<h2 class="main-heading">
								Managing hypoglycemia								
							</h2>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
						</div>
					</div>
					<div class="body">
						<div class="container">
							<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p>It is safer and more effective to prevent hypoglycemia than to t reat it after hypoglycemia occurs.<sup>11</sup> Counsel patients who are at high-risk for hypoglycemia on how to prevent low blood glucose.<sup>14</sup></p>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading">Hypoglycemia is defined by:<sup>14</sup></h6>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ol class="wp-block-list">
<li>The development of neurogenic or neuroglycopenic symptoms (see <a href="#hyposymptoms">Hypoglycemia symptoms</a>)</li>



<li>A low blood glucose level (&lt;4.0 mmol/L for people with diabetes treated with insulin or an insulin secretagogue)</li>



<li>The presence of symptoms that resolve following the intake of carbohydrates</li>
</ol>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading" id="hyposymptoms">Hypoglycemia symptoms<sup>14</sup></h3>
</div></article>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2021/05/nervous.png" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <h6>Neurogenic (autonomic)</h6>
<ul>
<li>Trembling</li>
<li>Palpitations</li>
<li>Sweating*</li>
<li>Anxiety</li>
<li>Hunger</li>
<li>Nausea</li>
<li>Tingling</li>
</ul>
          </div>
        </div>

      </div>
</article></div>



<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2021/05/brain.png" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <h6>Neuroglycopenic</h6>
<ul>
<li>Difficulty concentrating</li>
<li>Confusion</li>
<li>Weakness</li>
<li>Drowsiness</li>
<li>Vision changes</li>
<li>Difficulty speaking</li>
<li>Headache*</li>
<li>Dizziness</li>
<li>Disturbed sleep*</li>
<li>Abnormal dreams*</li>
</ul>
          </div>
        </div>

      </div>
</article></div>
</div>


<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p style="font-size:12px">*Symptoms of nocturnal hypoglycemia</p>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading">Reducing hypoglycemia risk</h3>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h5 class="wp-block-heading">Education</h5>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Review hypoglycemia risk factors at each visit if possible (see <a href="#hyporiskfactors">Risk factors for severe hypoglycemia</a>)<sup>14</sup></li>



<li>Counsel patients, families and caregivers on risk factors and how to prevent, recognize and treat hypoglycemia (see <a href="https://link.cep.health/t2dm4" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Hypoglycemia low blood sugar in adults</a>)</li>



<li>Review the injection technique to reduce lipohypertrophy risk (lipohypertrophy increases severe hypoglycemia risk by 2.7 fold;<sup>73</sup> see <a href="#safeinjection">Safe insulin injection techniques and pen needle use</a>)</li>



<li>Connect high-risk patients to a Certified Diabetes Educator, Diabetes Education Program/Centre or collaborative support (e.g., registered nurse, nurse practitioner, pharmacist, dietitian, see <a href="https://link.cep.health/t2dminhtml8" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Local services for patients living with type 2 diabetes</a>)<sup>14</sup></li>
</ul>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h5 class="wp-block-heading">Monitor</h5>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Support patients to self-monitor blood glucose more often</li>



<li>Consider a flash or continuous glucose monitoring system<sup>14</sup><article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>If readings are &lt; 4.0mmol/L, test the glucose monitoring system accuracy using a fingerprick</li>
</ul>
</div></article></li>



<li>For nocturnal hypoglycemia: advise patients to monitor their blood glucose levels periodically at the peak action time of their overnight insulin (use a glucose monitor that gives al erts based on blood glucose levels, e.g., DexCom® 6, FreeStyle Libre® 2 or FreeStyle Libre® combined with NightRider BluCon®)<sup>14</sup></li>
</ul>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h5 class="wp-block-heading">Reassess targets</h5>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Reassess whether targets are appropriate for the patient</li>



<li>If patient has hypoglycemia unawareness or pseudohypoglycemia, may consider less stringent glycemic targets with avoidance of hypoglycemia signs or symptoms for up to 3 months<sup>14</sup></li>
</ul>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h5 class="wp-block-heading">Adjust medication</h5>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Consider using medication (see <a href="https://link.cep.health/t2dminhtml47" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Type 2 diabetes: non-insulin pharmacotherapy</a>) and insulin (e.g., long-acting insulin) with a lower risk of hypoglycemia<sup>14</sup></li>



<li>Stop sulfonylureas when prandial (bolus) insulin is added to basal insulin<sup>2</sup></li>



<li>Consider reducing basal insulin dose by 10-20% if adding another non-insulin agent (e.g., GLP1-RA, SGLT2i)<sup>74</sup></li>



<li>Adjust insulin regimen or ratio<sup>75</sup></li>
</ul>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading" id="hyporiskfactors">Risk factors for severe hypoglycemia</h3>
</div></article>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2021/05/pt.png" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <h6>Patient risk factors</h6>
<ul>
<li>Advancing age and frailty<sup>14,76</sup></li>
<li>Female gender<sup>77</sup></li>
<li>Low A1C (&lt;6.0%)<sup>14</sup></li>
<li>Hypoglycemia unawareness<sup>14</sup>**</li>
<li>Prior episode of severe hypoglycemia<sup>14</sup></li>
<li>Long duration of diabetes (insulin insufficiency)<sup>76</sup></li>
<li>Neuropathy<sup>14</sup></li>
<li>Renal impairment (for eGFR &lt;30, consider adjusting insulin dose and timing to minimize insulin stacking)<sup>14,76</sup></li>
<li>Cognitive impairment<sup>14</sup></li>
<li>Poor health literacy<sup>14</sup></li>
<li>Food insecurity or erratic eating patterns<sup>3, 62</sup></li>
</ul>
          </div>
        </div>

      </div>
</article></div>



<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2021/05/meds.png" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <h6>Medication risk factors</h6>
<ul>
<li>Use of insulin<sup>78</sup></li>
<li>Long-term use of insulin therapy<sup>14</sup></li>
<li>Basal insulin component too high<sup>78</sup></li>
<li>Prandial (bolus) insulin doses not adjusted for physical activity, carbohydrate intake or skipped meals<sup> 76</sup></li>
<li>Not adjusting medications after weight loss or withdrawal of medications that raise blood glucose (e.g., corticosteroids)<sup>76</sup></li>
<li>Insulin mistakes (e.g., administering prandial (bolus) insulin at bedtime on an empty stomach instead of basal insulin)</li>
<li>Insulin stacking (e.g., injecting insulin correction within 3 hours of a previous correction)</li>
<li>Overbasalization (e.g., titration of basal insulin beyond an appropriate dose in an attempt to achieve glycemic targets)<sup>69</sup></li>
<li>Lipohypertrophy<sup>73</sup></li>
<li>Drugs that cause or mask symptoms of hypoglycemia (e.g., anti-hyperglycemics, beta blockers, ACE inhibitors, ethanol, fluoroquinolones, salicylates)<sup>79</sup></li>
</ul>
          </div>
        </div>

      </div>
</article></div>
</div>


<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p style="font-size:12px">**Hypoglycemia unawareness occurs when the threshold for the development of neurogenic warning symptoms is close to, or lower than, the threshold for the neuroglycopenic symptoms, such that the first sign of hypoglycemia is confusion or loss of consciousness. Frequent hypoglycemia can lead to hypoglycemia unawareness by decreasing normal responses to hypoglycemia. Hypoglycemia unawareness can be improved or reversed by strictly avoiding hypoglycemia for up to 3 months.<sup>14</sup></p>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading">Range of hypoglycemia severity<sup>14</sup></h3>
</div></article>

<article class="block--image  core-block" data-block-name="core/image"><div class="container">
<figure class="wp-block-image size-large is-style-default"><img loading="lazy" decoding="async" width="2300" height="422" src="https://tools.cep.health/wp-content/uploads/2021/04/Range-of-hypoglycemia-severity.png" alt="" class="wp-image-30837"/></figure>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading">Treating hypoglycemia<sup>14</sup></h3>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Hypoglycemia treatment aims to promptly increase low blood glucose to a safe level to eliminate the risk of injury and relieve symptoms</li>



<li>Avoid over-treatment, which can result in rebound hyperglycemia and weight gain</li>
</ul>
</div></article>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow" style="flex-basis:60%"><article class="block--faq "><div class="container">
    <div class="faq-title-wrapper">
        <div class="faq-icon-wrapper">
            <img decoding="async" class="faq-icon" src="https://tools.cep.health/wp-content/uploads/2020/05/info-icon.svg" alt="" />
        </div>
        <h3 class="faq-title"><h3>Select for treatment details</h3></h3>
    </div>
            <div class="questions">
                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Mild-moderate hypoglycemia</h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <ol>
<li>Oral ingestion of 15g carbohydrate (glucose or sucrose tablets/ solution preferred*)<sup>14</sup></li>
<li>Re-test blood glucose in 15 minutes. If the blood glucose level remains at &lt;4.0 mmol/L, re-treat with another 15g carbohydrate<sup>14</sup></li>
<li>Once the hypoglycemia is reversed, eat the usual meal/snack tha t is due at that time of day. If a meal is &gt;1 hour away, eat a snack with 15g carbohydrate and a protein source<sup>14</sup></li>
</ol>
<p><span style="font-size: 12px;">*People taking an alpha glucosidase inhibitor (acarbose) must use glucose (dextrose) tablets or, if unavailable, milk or honey to treat hypoglycemia.<sup>14</sup></span></p>
                        </div>
                    </div>
                                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Severe hypoglycemia</h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <p><strong>Conscious patient</strong></p>
<ol>
<li>Oral ingestion of 20g carbohydrate (glucose tablets or equivalent preferred*)<sup>14</sup></li>
<li>Re-test blood glucose in 15 minutes. If the blood glucose level remains at &lt;4.0 mmol/L, re-treat with another 15g carbohydrate<sup>14</sup></li>
<li>Once the hypoglycemia is reversed, eat the usual meal/snack that is due at that time of day. If a meal is &gt;1 hour away, eat a snack with 15g carbohydrate and a protein source<sup>14</sup></li>
</ol>
<p><strong>Unconscious patient (with no intravenous access)<br />
</strong></p>
<ol>
<li>Caregiver or support person should administer 1mg of glucagon subcutaneously or intramuscularly, or 3mg intranasally (see <a href="#glucagon">Glucagon as treatment for severe hypoglycemia</a>)<sup>14</sup><sup>,80</sup></li>
<li>Caregiver or support person should call for emergency services and notify the care team as soon as possible<sup>14</sup></li>
<li>Once the hypoglycemia is reversed, patient should eat the usual meal/snack that is due at that time of day. If a meal is &gt;1 hour away, eat a snack with 15g carbohydrate and a protein source<sup>14</sup></li>
</ol>
<p><strong>Unconscious patient (with intravenous access)</strong></p>
<ol>
<li>Caregiver or support person should administer 10-25g (20–50 mL of D50W) glucose intravenously over 1-3 minutes<sup>14</sup></li>
<li>Caregiver or support person should call for emergency services and notify the care team as soon as possible<sup>14</sup></li>
<li>Once the hypoglycemia is reversed, patient should eat the usual meal/snack that is due at that time of day. If a meal is &gt;1 hour away, eat a snack with 15g carbohydrate and a protein source<sup>14</sup></li>
</ol>
<p><span style="font-size: 12px;">*People taking an alpha glucosidase inhibitor (acarbose) must use glucose (dextrose) tablets or, if unavailable, milk or honey to treat hypoglycemia.<sup>14</sup></span></p>
                        </div>
                    </div>
                                    </div>
    </div></article></div>



<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow" style="flex-basis:40%"><article class="block--table ">
<div class="container">
  <div class="table  inner-border-grey blue">

                    <header>
                <h6><strong>Examples of 15g of carbohydrate:<sup>2</sup></strong></h6>
            </header>
        
                    <div class="rows">

                                    <div class="row">

                                                    <div class="cols">
                        
                                
                                                                            <div class="col 1" style="flex-basis:33%;">
                                            <ul>
<li>4 glucose/sucrose tablets (most tablets are 4g each)</li>
<li>15mL (1 tbsp) of sugar dissolved in water</li>
<li>3 packets of sugar from fast food/restaurants</li>
<li>5 cubes of sugar</li>
<li>150 mL (2/3 cup) of juice or regular soft drink</li>
<li>6 Life Savers® (each is 2.5g of carbohydrate)</li>
<li>15 mL (1 tbsp) of honey</li>
</ul>
                                        </div>
                                    
                                                            </div>
                        
                    </div>
                
            </div>
        
        
    </div>
</div>
</article></div>
</div>


<article class="block--background  core-block" data-block-name="cep/background"><div class="container">
<div class="wp-block-cep-background is-style-blue-background"><article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading"><strong>Troubleshooting hypoglycemia when A1C is above target</strong></h6>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Treat the low blood glucose first</li>



<li>Identify reasons for low blood glucose (e.g., skipped meal, exercise, too much insulin, sulfonylurea)</li>



<li>Review with the patient how to properly treat low blood glucose (some patients may take too much carbohydrate causing hyperglycemia)</li>
</ul>
</div></article></div>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading" id="glucagon">Glucagon as treatment for severe hypoglycemia</h3>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Glucagon should be prescribed to patients who experience or are at high risk of experiencing severe.hypoglycemia (e.g., those on long-term use of insulin who produce little to no insulin on their own, those at risk of insulin mistakes)</li>



<li>Glucagon is to be administered by a caregiver or support person (1mg subcutaneously/intramuscularly or 3mg intranasally) to a patient experiencing a severe hypoglycemic reaction when impaired consciousness precludes oral carbohydrates<sup>14,80</sup></li>



<li>Intranasal and intramuscular/subcutaneous glucagon are similarly effective. Some studies however, demonstrate that intramuscular/subcutaneous glucagon may be slightly more effective.<sup>82,83</sup> Intranasal glucagon may be preferred due to ease of use, and intramuscular/subcutaneous glucagon may be preferred due to lower cost.<sup>84</sup></li>
</ul>
</div></article>

<article class="block--drug-options ">
<div class="container">
  <h5><span style="font-size: 13.5px;">Scroll (left-right) for details</h5>
          <div class="slider">
        <div class="inner-stage">
          <ul>
            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Intranasal glucagon (Baqsimi®) <sup>80</sup></h6>
                    <p><strong>Coverage<sup>53,54</sup></strong></p>
<ul>
<li>ODB ✓ (<a href="https://link.cep.health/t2dminhtml54" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Limited Use: 625<sup>81</sup></a>)</li>
<li>NIHB X</li>
</ul>
<p><strong>Dosage forms<sup>53</sup></strong></p>
<ul>
<li>3mg prefilled device</li>
</ul>
<p><strong>Usual dose</strong></p>
<ul>
<li>3mg IN<sup>80</sup></li>
</ul>
<p><strong>Cost for usual dose</strong></p>
<ul>
<li>T: $165</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="oSMxw4">Comments</a>
                                      </div>
                                      <div class="modal" data-modal="oSMxw4">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Comments</h4>
                                                                                      <p><strong>Time to treatment response:</strong></p>
<ul>
<li style="list-style-type: none;">
<ul>
<li>Mean: 16.2 mins<sup>83</sup></li>
<li>Median: 10 (range 5-25) mins<sup>83</sup></li>
</ul>
</li>
<li>Time required to administer: 1 min<sup>84</sup></li>
<li>Inhalation is not required by the patient<sup>83</sup></li>
<li>Advantages:
<ul>
<li>Preferred due to ease of use<sup>84</sup></li>
<li>Higher rate of administration success<sup>83</sup></li>
<li>No refrigeration required<sup>80</sup></li>
</ul>
</li>
<li>Disadvantages:
<ul>
<li>Administration-related oronasopharyngeal and eye side effects (e.g., nasal discomfort, nasal congestion, nasal itching, sneezing, increased lacrimation, upper respiratory tract irritation)<sup>83</sup></li>
<li>Other side effects: nausea, vomiting, headache, fatigue<sup>83,84</sup></li>
</ul>
</li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Intramuscular/ subcutaneous glucagon (GlucaGen®, GlucaGen HypoKit®)<sup>85,86</sup></h6>
                    <p><strong>Coverage<sup>53,54</sup></strong></p>
<ul>
<li>ODB ✓</li>
<li>NIHB ✓</li>
</ul>
<p><strong>Dosage forms<sup>53</sup></strong></p>
<ul>
<li>1mg vial (HypoKit® includes vial and prefilled syringe with diluent)</li>
</ul>
<p><strong>Usual dose</strong></p>
<ul>
<li>1mg IM/SC<sup>85,86</sup></li>
</ul>
<p><strong>Cost for usual dose</strong></p>
<ul>
<li>G: $122</li>
<li>T: $124</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="tIbyEN">Comments</a>
                                      </div>
                                      <div class="modal" data-modal="tIbyEN">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Comments</h4>
                                                                                      <ul>
<li>Time to treatment response:
<ul>
<li>Mean: 12.2 mins<sup>83</sup></li>
<li>Median: 10 (range 10-20) mins<sup>83</sup></li>
</ul>
</li>
<li>Time required to administer: 1.3-5 mins<sup>84</sup></li>
<li>Advantages:
<ul>
<li>Less oronasopharyngeal and eye symptoms<sup>83</sup></li>
<li>No refrigeration required for GlucaGen HypoKit® (can be kept up to 18 months at room temperature) or generic IM/ SC glucagon (stored at room temperature)<sup>85,86</sup></li>
</ul>
</li>
<li>Disadvantages:
<ul>
<li>Refrigeration required for GlucaGen® <sup>85,86</sup></li>
<li>Administration-related side effects (e.g., injection site pain and irritation)<sup>83</sup></li>
<li>Other side effects: nausea, vomiting, vertigo<sup>83,84</sup></li>
</ul>
</li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

                      </ul>
        </div>
      </div>
    </div>
</article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p style="font-size:12px"><strong>IN</strong> = intranasal, <strong>IM</strong> = Intramuscular, <strong>G</strong> = generic, <strong>mg</strong> = milligram, <strong>SC</strong> = subcutaneous, <strong>T</strong> = trade</p>
</div></article>						</div>
					</div>
				</section>
							<section class="main-section" id="troubleshooting-common-insulin-situations" tabindex="-1">
					<div class="head">
						<div class="container">
							<h2 class="main-heading">
								Troubleshooting common insulin situations								
							</h2>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
						</div>
					</div>
					<div class="body">
						<div class="container">
							<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p>There are a number of situations that patients taking insulin should be aware of how to troubleshoot.</p>
</div></article>

<article class="block--faq "><div class="container">
    <div class="faq-title-wrapper">
        <div class="faq-icon-wrapper">
            <img decoding="async" class="faq-icon" src="https://tools.cep.health/wp-content/uploads/2020/05/info-icon.svg" alt="" />
        </div>
        <h3 class="faq-title"><h3>Select common insulin situation for details</h3></h3>
    </div>
            <div class="questions">
                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Sick day management</h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <ul>
<li><strong>Counsel patients as follows when they are sick (e.g., vomiting, diarrhea, fever, dehydration):</strong>
<ul>
<li>Monitor blood glucose more often (e.g., every 1-2 hours)</li>
<li>If at risk of dehydration (i.e., cannot keep food/liquid down), temporarily stop agents from the SADMANS list (see <a href="https://link.cep.health/t2dminhtml14" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Type 2 diabetes and sick days: Medications to pause</a>):
<ul>
<li><strong>S</strong>ecretagogues (e.g., gliclazide, glyburide, repaglinide)</li>
<li><strong>A</strong>CE inhibitors</li>
<li><strong>D</strong>iuretics, direct renin inhibitors</li>
<li><strong>M</strong>etformin</li>
<li><strong>A</strong>RBs</li>
<li><strong>N</strong>SAIDS</li>
<li><strong>S</strong>GLT2is</li>
</ul>
</li>
<li>Adjust insulin amount depending on changes in food/liquid intake</li>
<li>When feeling better (i.e., able to eat/drink well), restart agents from the SADMANS list and regular insulin routine</li>
</ul>
</li>
</ul>
                        </div>
                    </div>
                                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS)</h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <ul>
<li><strong>Risk factors<sup>14</sup></strong>
<ul>
<li>Type 1 diabetes (4.6-8 / 1,000 patient-years), type 2 diabetes (0.32-2 / 1,000 patient-years)<sup>88,89</sup></li>
<li>New diabetes diagnosis</li>
<li>Non-adherence to insulin therapy</li>
<li>Severe infection</li>
<li>Surgery</li>
<li>Trauma</li>
<li>Myocardial infarction</li>
<li>Stroke</li>
<li>Thyrotoxicosis</li>
<li>Use of specific medications and drugs (e.g., SGLT2i, cocaine, atypical antipsychotics, interferon, diuretics, glucocorticoids, lithium)</li>
<li>Ultra low carb or keto diet</li>
</ul>
</li>
<li><strong>Pregnant patients</strong>
<ul>
<li>Pregnant patients in DKA typically present with lower blood glucose levels than non-pregnant patients</li>
<li>There are case reports of euglycemic DKA in pregnancy</li>
</ul>
</li>
<li><strong>Clinical presentation of DKA</strong>
<ul>
<li>Symptoms: Urge to breathe deeply, nausea, vomiting, abdominal pain, altered sensorium</li>
<li>Signs: Kussmaul respiration, acetone-odoured (fruity-smelling) breath</li>
</ul>
</li>
<li><strong>Clinical presentation of HHS<br />
</strong></p>
<ul>
<li>Symptoms: Polyuria, polydipsia, weakness</li>
<li>Signs: Extracellular fluid volume depletion, seizures, stroke-like state</li>
</ul>
</li>
<li><strong>Management of mild DKA at home (mild = alert; not drowsy, not in stupor or coma)<sup>14</sup></strong>
<ul>
<li>In usual care, patients can self-manage early DKA if clinically stable and able to drink fluids</li>
<li>Monitor every 1-2 hours: blood glucose, nausea, vomiting, extreme thirst, ketones (with a reader/meter that accepts ketone strips, e.g., FreeStyle Libre®, FreeStyle Insulinx®, FreeStyle Precision Neo®)</li>
</ul>
</li>
<li><strong>Hospitalization<sup>14</sup></strong>
<ul>
<li>For patients with clinical decline (and/or a positive ketone test), recommend an evaluation at the emergency department given the concern of a rapid clinical decline (patients should not drive themselves)</li>
</ul>
</li>
</ul>
                        </div>
                    </div>
                                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Physical activity</h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <ul>
<li>Encourage patients to participate in regular physical activity</li>
<li>Insulin dose adjustments may be needed due to physical activity
<ul>
<li>Exact insulin dose adjustments cannot be provided</li>
<li>Adjustments will range (e.g., minimal to 50%), depending on the type/duration of exercise and blood glucose levels</li>
</ul>
</li>
<li><strong>Counsel patients who plan to participate in physical activity:<sup>90,91</sup></strong>
<ul>
<li>Monitor blood glucose before, during and a few hours after any physical activity</li>
<li>Adjust insulin as needed</li>
<li>Always carry rapid-acting carbohydrates (e.g., dextrose tablets)</li>
<li>Consider insulin timing when physical activity is planned</li>
<li>Avoid injecting insulin into subcutaneous tissue next to the primary muscle used (activity will increase insulin absorption)</li>
<li>Eat before before any physical activity</li>
<li>Ensure proper hydration and watch for signs and symptoms of dehydration (e.g., increased thirst, nausea, severe fatigue, blurred vision or headache)<sup>14</sup></li>
</ul>
</li>
</ul>
                        </div>
                    </div>
                                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Driving</h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <ul>
<li><strong>Risk</strong>
<ul>
<li>Diabetes, the use of insulin and its complications can affect driving performance.</li>
<li>Possible risks include: impaired sensory or motor function, impaired cognition, diabetic eye disease, nerve damage, kidney disease, cardiovascular disease, peripheral vascular disease, stroke and incidents of hypoglycemia<sup>14</sup></li>
</ul>
</li>
<li><strong>Assessment</strong>
<ul>
<li>All drivers taking insulin should have fitness to drive assessed every 2 years<sup>14</sup></li>
<li>Driver’s license may be suspended if a patient is determined unfit to drive or experiences an accident caused by hypoglycemia<sup>92</sup></li>
<li>Medical professionals in Ontario have a legal obligation to report to the appropriate regulatory body patients who have conditions that impair their driving ability (see <a href="https://link.cep.health/t2dminhtml49" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Reporting a driver for medical review</a>).<sup>14,93</sup></li>
</ul>
</li>
<li><strong>Counsel patients on insulin secretagogues and/or insulin to (see <a href="https://link.cep.health/t2dminhtml15" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Drive safe with diabetes</a>):<sup>14</sup></strong>
<ul>
<li>Measure blood glucose levels immediately before driving (must be &gt;4.0 mmol/L)</li>
<li>Re-test at least every 4 hours while driving
<ul>
<li>At least every 2 hours if the patient has a history of severe hypoglycemic episodes (e.g., loss of consciousness) or hypoglycemia unawareness (e.g., lack of early warning symptoms of hypoglycemia, such as tremor, sweatiness and palpitations)</li>
</ul>
</li>
<li>If blood glucose &lt;4.0 mmol/L, treat hypoglycemia (i.e., ingestion of 15g of carbohydrate). Re-test and wait 40 minutes after blood glucose returns to &gt;4.0 mmol/L before driving</li>
<li>Eat next meal or snack (containing carbohydrate and protein) within an hour</li>
<li>Always keep an emergency supply of fast-acting carbohydrates (e.g., dextrose tablets) and a glucose monitoring system inside the vehicle</li>
</ul>
</li>
<li><strong>Commercial vehicle licensing<sup>14,92</sup></strong>
<ul>
<li>Canadians with diabetes (with or without insulin) can be licensed to drive a commercial vehicle in Canada (and now the United States) if medical standards are met.</li>
</ul>
</li>
</ul>
                        </div>
                    </div>
                                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Lipohypertrophy<sup>66</sup></h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <div style="width: 55%; padding: 20px 70px 0 0; float: left;">
<ul>
<li><strong>Presentation</strong>
<ul>
<li>Lipohypertrophic area(s) can develop under the skin where the same injection or infusion site is used repeatedly</li>
<li>Lipohypertrophy usually presents as thickened or rubbery lesions (can vary in size and shape).</li>
<li>Some lesions are easily seen (e.g., a large bulge), while others require detected by palpation (e.g., a hard lump) or ultrasound</li>
</ul>
</li>
<li><strong>Risk factors</strong></li>
<li style="list-style-type: none;">
<ul>
<li>Lipohypertrophy can develop from repeated use of the same area, reusing insulin needles, more frequent insulin injections, higher dose insulin and a lack of systematic rotation<br />
<figure><img loading="lazy" decoding="async" class="" src="https://tools.cep.health/wp-content/uploads/2021/04/Screen-Shot-2021-04-23-at-11.44.53-AM.png" alt="" width="217" height="230" /></figure>
</li>
</ul>
</li>
</ul>
</div>
<div style="width: 55%; padding: 20px 70px 20px 0; float: left;">
<ul>
<li><strong>Effect of insulin</strong>
<ul>
<li>Lipohypertrophy can decrease the rate of insulin absorption or make it more erratic/delayed, resulting in higher doses of insulin needed to achieve glycemic targets</li>
</ul>
</li>
<li><strong>Prevention</strong>
<ul>
<li>Assess patients on insulin regularly for lipohypertrophy</li>
<li>Palpate injection area(s) regularly during patient appointments</li>
<li>Counsel patients on proper insulin injection techniques and pen needle use (see <a href="#safeinjection">Safe insulin injection techniques and pen needle use</a>)</li>
</ul>
</li>
<li><strong>Treatment</strong>
<ul>
<li>Have patient avoid injecting in the site</li>
<li>Lipohypertrophy may take 3-6 months to reduce or resolve</li>
</ul>
</li>
</ul>
</div>
                        </div>
                    </div>
                                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Insulin and pre-surgery/procedure<sup>94</sup></h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <ul>
<li><strong>Counsel patients</strong>
<ul>
<li>Night before surgery
<ul>
<li>Consider reducing long-acting, intermediate-acting or premixed insulin by 20-25%</li>
<li>Stop prandial (bolus) insulin when fasting begins</li>
</ul>
</li>
<li>Morning of surgery (defer to any pre-op information patient has been given if available)
<ul>
<li>Patients on a twice-daily dosing of basal insulin should consider reducing the normal morning dose by 20%</li>
<li>If morning blood glucose &gt; 6.7 mmol/L: reduce intermediate-acting or premixed insulin to 50% of the usual dose</li>
<li>If morning blood glucose &lt; 6.7 mmol/L: do not take intermediate-acting or premixed insulin. This will minimize the risk of hypoglycemia</li>
</ul>
</li>
</ul>
</li>
</ul>
                        </div>
                    </div>
                                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Travel<sup>95-97</sup></h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <ul>
<li>The primary goal is to avoid/prevent hypoglycemia during travel</li>
<li>Counsel patients on general diabetes travel tips (see <a href="https://link.cep.health/t2dminhtml16" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Air travel: Traveling can be a breeze if you follow a few tips</a>)</li>
<li>Recommendations for insulin adjustment during air travel vary significantly and are mostly based on expert opinion</li>
</ul>
<p><img loading="lazy" decoding="async" class="" src="https://tools.cep.health/wp-content/uploads/2021/04/Screen-Shot-2021-04-21-at-3.41.32-PM.png" alt="" width="1025" height="642" /></p>
                        </div>
                    </div>
                                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Specific diets</h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <ul>
<li>Refer patients with specific diet requirements to a dietitian ( see <a href="https://link.cep.health/t2dminhtml8" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Local services for patients living with type 2 diabetes</a>)</li>
<li>For information on common specific diets for patients with type 2 diabetes:
<ul>
<li><a href="https://link.cep.health/t2dminhtml45" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Patients observing Ramadan</a><sup>98</sup></li>
<li><a href="https://link.cep.health/t2dminhtml50" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Low carbohydrate diets</a><sup>99</sup></li>
<li>I<a href="https://link.cep.health/t2dminhtml51" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">ntermittent fasting</a><sup>100</sup></li>
</ul>
</li>
</ul>
<p>&nbsp;</p>
                        </div>
                    </div>
                                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Glucocorticoid-induced hyperglycemia<sup>101,102</sup></h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <ul>
<li>Glucocorticoid-induced hyperglycemia can occur in patients with or without diabetes</li>
<li><strong>Monitoring</strong>
<ul>
<li>Monitor blood sugar three times daily</li>
</ul>
</li>
<li><strong>Indications to consider treatment</strong>
<ul>
<li>Blood glucose &gt;12 mmol/L on two occasions within a 24-hour period (consider checking ketones if indicated)</li>
</ul>
</li>
<li><strong>Treatment options</strong>
<ul>
<li>If NOT on insulin: adding a sulfonylurea or adjusting current sulfonylurea dose may be considered. Insulin may be needed.</li>
<li>If ON insulin: adjust basal insulin daily (may need &gt;30% increase)</li>
<li>Treatment considerations should be individualized based on glucocorticoid drug (e.g., prednisone has mid-day peak, dexamethasone is longer acting), treatment duration, and patient risks of hyperglycemia and hypoglycemia. A second opinion from a specialist may be considered (e.g., e-Consult)</li>
<li>Careful monitoring and subsequent decreases in antihyperglycemic therapy is prudent when steroid dose is tapered and/or when clinical status changes</li>
</ul>
</li>
</ul>
                        </div>
                    </div>
                                    </div>
    </div></article>						</div>
					</div>
				</section>
							<section class="main-section" id="patient-resources" tabindex="-1">
					<div class="head">
						<div class="container">
							<h2 class="main-heading">
								Patient resources								
							</h2>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
						</div>
					</div>
					<div class="body">
						<div class="container">
							<article class="block--support-materials ">

  <div class="container default">
    <div class="inner">
              <div class="columns">
                      <div class="column icon">
              <img decoding="async" src="https://tools.cep.health/wp-content/themes/cep-tools/img/support-materials.svg" />
            </div>
                                <div class="column">
              <strong class="heading">Resources</strong>
            </div>
                  </div>
                    <ul>
<li><a href="https://link.cep.health/t2dminhtml56" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Biosimilars</a>: Information for patients from Ontario’s Ministry of Health, and financial support programs for patients prescribed <a href="https://link.cep.health/t2dminhtml57" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Semglee®</a> and <a href="https://link.cep.health/t2dminhtml58" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Kirsty®</a>.</li>
<li><a href="https://link.cep.health/t2dminhtml8" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Local services for patients living with type 2 diabetes</a></li>
<li><a href="https://link.cep.health/t2dminhtml10" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Forum for Injection Technique (FIT) technique plus</a></li>
<li><a href="https://link.cep.health/t2dminhtml12" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Diabetes Canada Glycemic index food guide</a></li>
<li><a href="https://link.cep.health/t2dm4" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Diabetes Canada Hypoglycemia low blood sugar in adults</a></li>
<li><a href="https://link.cep.health/t2dminhtml14" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">RxFiles Type 2 diabetes and sick days: Medications to pause</a></li>
<li><a href="https://link.cep.health/t2dminhtml78" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Diabetes Canada Drive safe with diabetes</a></li>
<li><a href="https://link.cep.health/t2dminhtml16" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Diabetes Canada Air travel: Traveling can be a breeze if you follow a few tips</a></li>
</ul>
          </div>
  </div>

</article>						</div>
					</div>
				</section>
							<section class="main-section" id="references" tabindex="-1">
					<div class="head">
						<div class="container">
							<h2 class="main-heading">
								References								
							</h2>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
						</div>
					</div>
					<div class="body">
						<div class="container">
							<article class="block--references ">
<div class="container">

                        <ul>
               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [1]
                    </div>

                    <div class="column">
                      <p>RxTx. Diabetes mellitus. 2020.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [2]
                    </div>

                    <div class="column">
                      <p>Lipscombe L, Butalia S, Dasgupta K, Eurich DT, MacCallum L, Shah BR, et al. Pharmacologic glycemic management of type 2 diabetes in adults: 2020 update. Canadian Journal of Diabetes. 2020 Oct 1;44(7):575–91.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [3]
                    </div>

                    <div class="column">
                      <p>The EMPA-KIDNEY Collaborative Group, Herrington W.G., Staplin N, Wanner C, Green J.B, Hause S.J., Emberson J.R., et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023 Jan 12;388(2):117-127.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [4]
                    </div>

                    <div class="column">
                      <p>Solomon S.D., McMurray J.J.V., Claggett B, de Boer R.A., DeMets D, Hernandez A.F., Inzucchi S.E., et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2022; 387:1089-1098.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [5]
                    </div>

                    <div class="column">
                      <p>Packer M, Anker S.D., Butler J, Filippatos G, Pocock S.J., Carson P, Januzzi J, Verma S, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020; 383:1413-1424.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [6]
                    </div>

                    <div class="column">
                      <p>McMurray J.J.V., Solomon S.D., Inzucchi S.E., Køber L, Kosiborod M.N., Martinez F.A., Ponikowski P, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381:1995-2008.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [7]
                    </div>

                    <div class="column">
                      <p>Heerspink H.J.L., Stefánsson B.V., Correa-Rotter R, Chertow G.M., Greene T, Hou F.F., et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383:1436-1446.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [8]
                    </div>

                    <div class="column">
                      <p>American Diabetes Association. Introduction: Standards of medical care in diabetes &#8211; 2021. DiaCare. 2021 Jan;44(Supplement 1):S1–2.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [9]
                    </div>

                    <div class="column">
                      <p>Senior PA, Houlden RL, Kim J, Mackay D, Nagpal S, Rabi D, et al. Pharmacologic glycemic management of type 2 diabetes in adults: 2020 update &#8211; The users guide. Canadian Journal of Diabetes. 2020 Oct 1;44(7):592–6.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [10]
                    </div>

                    <div class="column">
                      <p>Mayo Clinic. Hyperglycemia in diabetes &#8211; Symptoms and causes [Internet]. 2020 [cited 2021 Jan 14]. Available from: <a href="https://link.cep.health/t2dminhtml17" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">https://www.mayoclinic.org/diseases-conditions/hyperglycemia/symptomscauses/syc-20373631</a></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [11]
                    </div>

                    <div class="column">
                      <p><span style="font-weight: 400;">Diabetes Canada Clinical Practice Guidelines Expert Committee. Chapter 37: Diabetes in older people [Internet]. 2018 [cited (2023 Jun 23)]. Available from: <a href="https://link.cep.health/t2dminhmtl80" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">https://www.diabetes.ca/health-care-providers/clinical-practice-guidelines/chapter-37#panel-tab_FullText </a></span></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [12]
                    </div>

                    <div class="column">
                      <p>Kramer CK, Zinman B, Choi H, Retnakaran R. Predictors of sustained drug-free diabetes remission over 48 weeks following short-term intensive insulin therapy in early type 2 diabetes. BMJ Open Diab Res Care. 2016 Jul;4(1):e000270.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [13]
                    </div>

                    <div class="column">
                      <p>Koufakis T, Karras SN, Zebekakis P, Ajjan R, Kotsa K. Should the last be first? Questions and dilemmas regarding early short-term insulin treatment in Type 2 Diabetes Mellitus. Expert Opinion on Biological Therapy. 2018 Nov 2;18(11):1113–21.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [14]
                    </div>

                    <div class="column">
                      <p>Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada. Canadian Journal of Diabetes. 2018;42(Suppl 1):S1–325.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [15]
                    </div>

                    <div class="column">
                      <p>RxFiles. Type 2 diabetes: Strategies, drug therapy &amp; tools (2nd edition) [Internet]. 2020. Available from: <a href="https://link.cep.health/t2dminhtml19" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">www.rxfiles.ca</a></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [16]
                    </div>

                    <div class="column">
                      <p>Canadian Agency for Drugs and Technologies in Health. Guide to starting and adjusting insulin for type 2 diabetes. 2012 Jul. 5 pages.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [17]
                    </div>

                    <div class="column">
                      <p>Liu S-C, Tu Y-K, Chien M-N, Chien K-L. Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. Diabetes, Obesity and Metabolism. 2012;14(9):810–20.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [18]
                    </div>

                    <div class="column">
                      <p>Mearns ES, Sobieraj DM, White CM, Saulsberry WJ, Kohn CG, Doleh Y, et al. Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: A network meta-analysis. PLOS ONE. 2015;10(4):28.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [19]
                    </div>

                    <div class="column">
                      <p>Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: A systematic review and meta-analysis. Ann Intern Med. 2016 Jun 7;164(11):740.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [20]
                    </div>

                    <div class="column">
                      <p>Holmes RS, Crabtree E, McDonagh MS. Comparative effectiveness and harms of long-acting insulins for type 1 and type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab. 2019 Apr;21(4):984–92.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [21]
                    </div>

                    <div class="column">
                      <p>Madenidou A-V, Paschos P, Karagiannis T, Katsoula A, Athanasiadou E, Kitsios K, et al. Comparative benefits and harms of basal insulin analogues for type 2 diabetes: A systematic review and network meta-analysis. Ann Intern Med. 2018 Aug 7;169(3):165.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [22]
                    </div>

                    <div class="column">
                      <p>The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319-328.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [23]
                    </div>

                    <div class="column">
                      <p>Marso SP, Poulter NR, Pieber TR, Lange M, Skibsted S. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377:723-732.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [24]
                    </div>

                    <div class="column">
                      <p>Kongerkery S, Schroeder P, Shomali M. Insulin and its cardiovascular effects: What is the current evidence? Curr Diab Rep. 2017;17(120):1-8.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [25]
                    </div>

                    <div class="column">
                      <p>Swinnen SG, Simon AC, Holleman F, Hoekstra JB, DeVries JH. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Metabolic and Endocrine Disorders Group, editor. Cochrane Database of Systematic Reviews [Internet]. 2011 Jul 6 [cited 2021 Jan 13]; Available from: https://www.cochrane.org/CD006383/ENDOC_insulin-detemir-versus-insulin-glargine-for-type-2-diabetes-mellitus</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [26]
                    </div>

                    <div class="column">
                      <p>Government of Ontario, Ministry of Health. Bulletin 230302 &#8211; Biosimilar support fee code K900A [Internet]. 2023 [cited (2023 Jun 22)]. Available from: https://www.ontario.ca/document/ohip-infobulletins-2023/bulletin-230302-biosimilar-support-fee-code-k900a</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [27]
                    </div>

                    <div class="column">
                      <p>Semlitsch T, Engler J, Siebenhofer A, Jeitler K, Berghold A, Horvath K. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus. Cochrane Metabolic and Endocrine Disorders Group, editor. Cochrane Database of Systematic Reviews [Internet]. 2020 Nov 9 [cited 2021 Jan 13]; Available from: https://www.cochrane.org/CD005613/ENDOC_ultra-long-acting-insulin-analogues-compared-nph-insulin-human-isophaneinsulin-adults-type-2</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [28]
                    </div>

                    <div class="column">
                      <p>British Columbia Provincial Academic Detailing Service. Basal insulins for type 2 diabetes: How does insulin choice affect the risk of hypoglycemia and medication cost? [Internet]. 2019 [cited 2021 Jan 14]. Available from: https://www2.gov.bc.ca/assets/gov/health/practitioner-pro/provincial-academic-detailing-service/pad-2019-basal-insulins-type-2-diabetes-newsletter.pdf</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [29]
                    </div>

                    <div class="column">
                      <p>Canadian Agency for Drugs and Technologies in Health. Basal insulin formulations for the management of type 2 diabetes. 2021 Feb. 30 pages.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [30]
                    </div>

                    <div class="column">
                      <p>Yamada T, Kamata R, Ishinohachi K, Shojima N, Ananiadou S, Nom H, et al. Biosimilar vs originator insulins: Systematic review and meta-analysis. Diabetes Obes Metab. 2018 Jul;20(7):1787–92.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [31]
                    </div>

                    <div class="column">
                      <p>Zhou W, Tao J, Zhou X, Chen H. Insulin degludec, a novel ultra-long-acting basal insulin versus insulin glargine for the management of type 2 diabetes: A systematic review and meta-analysis. Diabetes Ther. 2019 Jun;10(3):835–52.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [32]
                    </div>

                    <div class="column">
                      <p>Fullerton B, Siebenhofer A, Jeitler K, Horvath K, Semlitsch T, Berghold A, et al. Short-acting insulin analogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetes mellitus. Cochrane Metabolic and Endocrine Disorders Group, editor. Cochrane Database of Systematic Reviews [Internet]. 2018 Dec 17 [cited 2021 Jan 13]; Available from: <a href="https://link.cep.health/t2dminhtml20" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">https://www.cochrane.org/CD013228/ENDOC_short-acting-insulin-analogues-versus-regular-human-insulintype-2-diabetes-mellitus</a></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [33]
                    </div>

                    <div class="column">
                      <p>Health Canada. Biosimilar biologic drugs in Canada: Fact sheet [Internet]. 2019 [cited (2023 Jun 22)]. Available from: https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/dhp-mps/alt_formats/pdf/brgtherap/applic-demande/guides/Fact-Sheet-EN-2019-08-23.pdf</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [34]
                    </div>

                    <div class="column">
                      <p>Government of Ontario, Ministry of Health, Health Programs and Delivery Division. Executive officer notice: Biosimilar policy [Internet]. 2023 [cited (2023 Jun 22)]. Available from: https://www.health.gov.on.ca/en/pro/programs/drugs/opdp_eo/notices/exec_office_eligibility_20230310.pdf</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [35]
                    </div>

                    <div class="column">
                      <p>Government of Ontario, Ministry of Health. Bulletin 230302 &#8211; Biosimilar support fee code K900A [Internet]. 2023 [cited (2023 Jun 22)]. Available from: https://www.ontario.ca/document/ohip-infobulletins-2023/bulletin-230302-biosimilar-support-fee-code-k900a</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [36]
                    </div>

                    <div class="column">
                      <p>Diabetes Canada. Diabetes, biologic drugs, and biosimilar insulins &#8211; Position statement [Internet]. 2020 [cited (2023 Jun 22)]. Available from: https://www.diabetes.ca/advocacy&#8212;policies/our-policy-positions/diabetes,-biologic-drugs,-and-biosimilar-insulins</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [37]
                    </div>

                    <div class="column">
                      <p>medSask. Transitioning to a biosimilar insulin [Internet]. 2023 [cited (2023 Jun 22)] Available from: https://medsasklive.usask.ca/sites/medsask/files/2023-03/medsask-insulin-transition-patient-tool-feb10-final.pdf</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [38]
                    </div>

                    <div class="column">
                      <p>Government of Ontario, Ministry of Health. Biosimilars: Information for patients [Internet]. 2023 [cited (2023 Jun 22)]. Available from: https://www.health.gov.on.ca/en/pro/programs/biosimilars/default.aspx</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [39]
                    </div>

                    <div class="column">
                      <p>Government of Ontario, Ministry of Health, Health Programs and Delivery Division. Biosimilar policy: Q&amp;A for pharmacists [Internet]. 2023 [cited (2023 Jun 22)]. Available from: https://www.health.gov.on.ca/en/pro/programs/drugs/opdp_eo/notices/fq_exec_office_pharm_20230310.pdf</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [40]
                    </div>

                    <div class="column">
                      <p>Government of Ontario, Ministry of Health. Formulary search: Limited use note(s) &#8211; Insulin glargine 100U/mL Sol-10mL vial pk [Internet]. 2021 [cited (2023 Jun 22)]. Available from: https://www.formulary.health.gov.on.ca/formulary/limitedUseNotes.xhtml?pcg9Id=682014009</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [41]
                    </div>

                    <div class="column">
                      <p>Government of Ontario, Ministry of Health. Formulary search: Limited use note(s) &#8211; Insulin aspart 100U/mL Sol-5x3mL pk [Internet]. 2021 [cited (2023 Jun 22)]. Available from: https://www.formulary.health.gov.on.ca/formulary/limitedUseNotes.xhtml?pcg9Id=682010022</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [42]
                    </div>

                    <div class="column">
                      <p>Government of Ontario, Ministry of Health. Formulary search: Results [Internet]. 2021 [cited (2023 Jun 22)] Available from: https://www.formulary.health.gov.on.ca/formulary/results.xhtml?man=NOO</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [43]
                    </div>

                    <div class="column">
                      <p>Government of Ontario, Ministry of Government and Consumer Services. Application for funding for insulinsyringes for seniors &#8211; Assistive Devices Program [Internet]. Government of Ontario, Ministry of Government and Consumer Services; [cited 2021 Jan 18]. Available from: http://www.forms.ssb.gov.on.ca/mbs/ssb/forms/ssbforms.nsf/FormDetail?OpenForm&amp;ACT=RDR&amp;TAB=PROFILE&amp;SRCH=1&amp;ENV=WWE&amp;TIT=3183&amp;NO=014-1429-67E</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [44]
                    </div>

                    <div class="column">
                      <p>Government of Canada. Non-insured health benefits program updates: April 2023 [Internet]. 2023 [cited (2023 Jun 22)]. Available from: https://www.sac-isc.gc.ca/eng/1578079214611/1578079236012#s23-04-a1</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [45]
                    </div>

                    <div class="column">
                      <p>RxTx. Insulin products. 2020.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [46]
                    </div>

                    <div class="column">
                      <p>Sanofi-aventis Canada Inc. Product monograph: Toujeo® [Internet]. 2019. Available from: https://pdf.hres.ca/dpd_pm/00053767.PDF</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [47]
                    </div>

                    <div class="column">
                      <p>Perfetti R. Reusable and disposable insulin pens for the treatment of diabetes: Understanding the global differences in user preference and an evaluation of inpatient insulin pen use. Diabetes Technology &amp; Therapeutics. 2010 Jun;12(S1):S-79-S-85.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [48]
                    </div>

                    <div class="column">
                      <p>Institute For Safe Medication Practices. Read this important information before taking: Lantus (insulin glargine) [Internet]. 2012 [cited 2021 Jan 14]. Available from: https://consumermedsafety.org/assets/ismp-Grant-Brochure-lantus-FEB2012-WEB.pdf</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [49]
                    </div>

                    <div class="column">
                      <p>Eli Lilly Canada Inc. Product monograph: Humalog® [Internet]. 2017 [cited 2021 Jan 14]. Available from: http://pi.lilly.com/ca/humalog-ca-pm.pdf</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [50]
                    </div>

                    <div class="column">
                      <p>FIT4Safety Canada. Recommendations for best practice in the safe use of diabetes sharps [Internet]. [cited 2021 Jan 14]. Available from: http://www.fit4diabetes.com/files/2714/4861/5848/FIT4Safety_English_lang.pdf</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [51]
                    </div>

                    <div class="column">
                      <p>Eli Lilly Canada Inc. Product monograph: EntuzityTM KwikPen® [Internet]. 2020 [cited 2021 Jan 14]. Available from: http://pi.lilly.com/ca/entuzity-ca-pm.pdf</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [52]
                    </div>

                    <div class="column">
                      <p>Beavers-Willis LA. Be earth-friendly with diabetes and medical supplies [Internet]. 2015 [cited 2021 Jan 14]. Available from: https://www.trinitytwincity.org/blog/2015/04/22/be-earth-friendlywithdiabetes-and-medical-supplies</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [53]
                    </div>

                    <div class="column">
                      <p>Government of Ontario, Ministry of Health. Ontario Drug Benefit Formulary [Internet]. [cited 2020 Aug 4]. Available from: <a href="https://link.cep.health/t2dminhtml23" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">https://www.formulary.health.gov.on.ca/formulary/</a></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [54]
                    </div>

                    <div class="column">
                      <p>Indigenous Services Canada. Non-insured health benefits, First Nations and Inuit Health Branch: Drug benefit list [Internet]. 2020. Available from: <a href="https://link.cep.health/t2dminhtml24" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">https://www.sac-isc.gc.ca/eng/1572888328565/1572888420703</a></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [55]
                    </div>

                    <div class="column">
                      <p>Novo Nordisk Canada Inc. Product monograph: Tresiba® [Internet]. 2019 [cited 2021 Jan 14]. Available from: <a href="https://link.cep.health/t2dminhmtl90" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">https://www.novonordisk.ca/content/dam/nncorp/ca/en/products/tresibaproductmonograph.pdf</a></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [56]
                    </div>

                    <div class="column">
                      <p>Hill J, Poole R. The effects of mixing different insulin analogues. European Diabetes Nursing. 2011;8(3):119–119.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [57]
                    </div>

                    <div class="column">
                      <p><a href="https://link.cep.health/expertopinionrationale" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Expert opinion</a>.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [58]
                    </div>

                    <div class="column">
                      <p>Government of Ontario, Ministry of Health. Formulary Search Limited use note(s): Insulin glargine [Internet]. 2022 [cited 2022 Mar 1]. Available from: https://www.formulary.health.gov.on.ca/formulary/limitedUseNotes.xhtml?pcg9Id=682014008</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [59]
                    </div>

                    <div class="column">
                      <p>BGP Pharma ULC. Product monograph including patient information: Semglee® [Internet]. 2022 [cited (2023 Jun 22)]. Available from: https://pdf.hres.ca/dpd_pm/00065501.PDF</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [60]
                    </div>

                    <div class="column">
                      <p>Government of Ontario, Ministry of Health. Formulary search Limited use note(s): Insulin lispro [Internet]. 2021 [cited 2021 Feb 2]. Available from: https://www.formulary.health.gov.on.ca/formulary/limitedUseNotes.xhtml?pcg9Id=682010031</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [61]
                    </div>

                    <div class="column">
                      <p>Sanofi-aventis Canada Inc. Product monograph: TrurapiTM [Internet]. 2021. Available from: https://pdf.hres.ca/dpd_pm/00061172.pdf.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [62]
                    </div>

                    <div class="column">
                      <p>Biocon Sdn Bhd. Product monograph including patient information: Kirsty® [Internet]. 2023 [cited (2023 Jun 22)]. Available from: https://pdf.hres.ca/dpd_pm/00070702.PDF</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [63]
                    </div>

                    <div class="column">
                      <p>Diabetes Canada. Self-monitoring blood glucose frequency and pattern tool [Internet]. 2018 [cited 2021 Feb 18]. Available from: <a href="https://link.cep.health/t2dmin51" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">http://guidelines.diabetes.ca/self-management/smbg-tool</a></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [64]
                    </div>

                    <div class="column">
                      <p>Diabetes Canada. Getting started with insulin [Internet]. 2018 [cited 2021 Feb 2]. Available from: <a href="https://link.cep.health/t2dminhtml37" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">https://www.diabetes.ca/DiabetesCanadaWebsite/media/Managing-My-Diabetes/Tools%20and%20Resources/getting-started-with-insulin-injections.pdf?ext=.pdf</a></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [65]
                    </div>

                    <div class="column">
                      <p>ConsumerMedSafety. Storage of insulin [Internet]. Institute for Safe Medication Practices; [cited 2021 Feb 9]. Available from: <a href="https://link.cep.health/t2dminhmtl87" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">https://consumermedsafety.org/tools-and-resources/insulinsafetycenter/storage-of-insulin</a></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [66]
                    </div>

                    <div class="column">
                      <p>FIT Forum for Injection Technique Canada. Recommendations for best practice in injection technique [Internet]. 2020 [cited 2021 Jan 19]. Report No.: 4th edition. Available from: <a href="https://link.cep.health/t2dminhtml39" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">https://www.fit4diabetes.com/files/7816/0803/3133/FIT_Recommendations_2020.pdf</a></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [67]
                    </div>

                    <div class="column">
                      <p>Bergenstal R, Peremislov D, Parvu V. Safety and efficacy of insulin therapy delivered via a 4mm pen needle in obees patients with diabetes. Mayo Clinic Proceedings. 2015;90(3):329–38.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [68]
                    </div>

                    <div class="column">
                      <p>Diabetes Canada. Insulin prescription [Internet]. 2017 [cited 2021 Jan 19]. Available from: <a href="https://link.cep.health/t2dminhtml11" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">https://www.diabetes.ca/DiabetesCanadaWebsite/media/Managing-My-Diabetes/Tools%20and%20Resources/insulin-prescription-fillable-EN.pdf?ext=.pdf</a></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [69]
                    </div>

                    <div class="column">
                      <p>Cowart K. Overbasalization: Addressing hesitancy in treatment intensification beyond basal insulin. Clinical Diabetes. 2020 Jul;38(3):304-310.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [70]
                    </div>

                    <div class="column">
                      <p>Wu T, Betty B, Downie M, Khanolkar M, Kilov G, Orr-Walker B, Senator G, Fulcher G. Practical guidance on the use of premix insulin analogs in initiating, intensifying, or switching insulin regimens in type 2 diabetes. Diabetes Ther. 2015 Apr;6:273–287.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [71]
                    </div>

                    <div class="column">
                      <p>Rodbard HW, Visco VE, Andersen H, Hiort LC, Shu DHW. Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEPStudy): a randomised, treat-to-target clinical trial. Lancet Diabetes Endocrinol. 2014 Jan;2(1):30–7.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [72]
                    </div>

                    <div class="column">
                      <p>Chun J, Strong J, Urquhart S. Insulin initiation and titration in patients with type 2 diabetes. Diabetes Spectrum. 2019 May; 32(2):104-111.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [73]
                    </div>

                    <div class="column">
                      <p>Pozzuoli GM, Laudato M, Barone M, Crisci F, Pozzuoli B. Errors in insulin treatment management and risk of lipohypertrophy. Acta Diabetol. 2018 Jan;55(1):67–73.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [74]
                    </div>

                    <div class="column">
                      <p>Anderson SL, Trujillo JM. Basal insulin use with GLP-1 receptor agonists. Diabetes Spectr. 2016 Aug;29(3):152–60.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [75]
                    </div>

                    <div class="column">
                      <p>McCall AL. Insulin therapy and hypoglycemia. Endocrinology and Metabolism Clinics of North America. 2012 Mar;41(1):57–87.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [76]
                    </div>

                    <div class="column">
                      <p>LeBras M, Laubscher T. Hypoglycemia in type 2 diabetes: It is common, so what strategies can minimize the risk? Canadian Family Physician. 2021 Jan;67(1):35-38.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [77]
                    </div>

                    <div class="column">
                      <p>Kautzky-Willer A, Kosi L, Lin J, Mihaljevic R. Gender-based differences in glycaemic control and hypoglycaemia prevalence in patients with type 2 diabetes: results from patient-level pooled data of six randomized controlled trials. Diabetes Obes Metab. 2015 Jun;17(6):533–40.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [78]
                    </div>

                    <div class="column">
                      <p>Czech M, Rdzanek E, Pawęska J, Adamowicz-Sidor O, Niewada M, Jakubczyk M. Drug-related risk of severe hypoglycaemia in observational studies: a systematic review and meta-analysis. BMC Endocr Disord. 2015 Dec;15(1):57.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [79]
                    </div>

                    <div class="column">
                      <p>Vue MH, Setter SM. Drug-induced glucose alterations part 1: Drug-induced hypoglycemia. Diabetes Spectrum. 2011 Aug 1;24(3):171–7.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [80]
                    </div>

                    <div class="column">
                      <p>Eli Lilly Canada Inc. Product monograph: BaqsimiTM [Internet]. 2019. Available from: <a href="https://link.cep.health/t2dminhtml41" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">https://pdf.hres.ca/dpd_pm/00053281.PDF</a></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [81]
                    </div>

                    <div class="column">
                      <p>Government of Ontario, Ministry of Health. Formulary Search Limited use note(s): Glucagon [Internet]. 2022 [cited 2022 Mar 10]. Available from: https://www.formulary.health.gov.on.ca/formulary/limitedUseNotes.xhtml?pcg9Id=920000739</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [82]
                    </div>

                    <div class="column">
                      <p>Boido A, Ceriani V, Pontiroli AE. Glucagon for hypoglycemic episodes in insulin-treated diabetic patients: a systematic review and meta-analysis with a comparison of glucagon with dextrose and of different glucagon formulations. Acta Diabetol. 2015 Apr;52(2):405–12.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [83]
                    </div>

                    <div class="column">
                      <p>Canadian Agency for Drugs and Technologies in Health. Clinical review report: Glucagon nasal powerder (Baqsimi). 2020 Mar. 82 pages.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [84]
                    </div>

                    <div class="column">
                      <p>Singh-Franco D, Moreau C, Levin AD, Rosa DDL, Johnson M. Efficacy and usability of intranasal glucagon for the management of hypoglycemia in patients with diabetes: A systematic review. Clinical Therapeutics. 2020 Sep;42(9):e177–208.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [85]
                    </div>

                    <div class="column">
                      <p>Novo Nordisk Canada Inc. Product monograph: Glucagen® and Glucagen® Hypokit [Internet]. 2016. Available from: <a href="https://link.cep.health/t2dminhtml42" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">https://www.paladin-labs.com/our_products/PM_GlucaGen_EN.pdf</a></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [86]
                    </div>

                    <div class="column">
                      <p>Eli Lilly Canada Inc. Product monograph: Glucagon [Internet]. 2012. Available from: <a href="https://link.cep.health/t2dminhtml43" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">https://pdf.hres.ca/dpd_pm/00017002.PDF</a></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [87]
                    </div>

                    <div class="column">
                      <p>RxFiles. Type 2 diabetes and sick day medications to pause [Internet]. [cited 2021 Jan 19]. Available from: <a href="https://link.cep.health/t2dminhtml14" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">https://www.rxfiles.ca/rxfiles/uploads/documents/SADMANS-Rx.pdf</a></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [88]
                    </div>

                    <div class="column">
                      <p>Wang ZH, Kihl-Selstam E, Eriksson JW. Ketoacidosis occurs in both Type 1 and Type 2 diabetes— a population-based study from Northern Sweden. Diabetic Medicine. 2008;25(7):867–70.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [89]
                    </div>

                    <div class="column">
                      <p>Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009 Jul 1;32(7):1335–43.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [90]
                    </div>

                    <div class="column">
                      <p>Zaharieva DP, Riddell MC. Insulin management strategies for exercise in diabetes. Canadian Journal of Diabetes. 2017 Oct 1;41(5):507–16.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [91]
                    </div>

                    <div class="column">
                      <p>Colberg SR, Sigal RJ, Yardley JE, Riddell MC, Dunstan DW, Dempsey PC, et al. Physical activity/exercise and diabetes: A position statement of the American Diabetes Association. Dia Care. 2016 Nov;39(11):2065–79.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [92]
                    </div>

                    <div class="column">
                      <p>Government of Ontario, Ministry of Transportation. Reporting a driver for medical review [Internet]. 2019 [cited 2021 Apr 07]. Available from: https://www.ontario.ca/page/reporting-drivermedical-review</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [93]
                    </div>

                    <div class="column">
                      <p>Government of Ontario, Ministry of Transportation. Medical review [Internet]. 2019 [cited 2021 Jan 19]. Available from: <a href="https://link.cep.health/t2dminhtml44" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">http://www.mto.gov.on.ca/english/safety/medical-review.shtml</a></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [94]
                    </div>

                    <div class="column">
                      <p>Duggan E, Chen Y. Glycemic management in the operating room: Screening, monitoring, oral hypoglycemics, and insulin therapy. Curr Diab Rep. 2019 Nov;19(11):134.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [95]
                    </div>

                    <div class="column">
                      <p>Pinsker JE, Becker E, Mahnke CB, Ching M, Larson NS, Roy D. Extensive clinical experience: a simple guide to basal insulin adjustments for long-distance travel. Journal of Diabetes and Metabolic Disorders [Internet]. 2013 Dec 20 [cited 2021 Jan 19];12(1).</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [96]
                    </div>

                    <div class="column">
                      <p>Jawad F, Kalra S. Diabetes and travel. Journal of Pakistan Medical Association. 2016 Oct;66(10):1347–8.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [97]
                    </div>

                    <div class="column">
                      <p>Pavela J, Suresh R, Blue RS, Mathers CH, Belalcazar LM. Management of diabetes during air travel: A systematic literature review of current recommendations and their supporting evidence. Endocrine Practice. 2018 Feb 1;24(2):205–19.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [98]
                    </div>

                    <div class="column">
                      <p>Diabetes Canada. Ramadan and diabetes [Internet]. 2019 [cited 2021 Feb 18]. Available from: <a href="https://link.cep.health/t2dminhtml45" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">https://guidelines.diabetes.ca/healthcareprovidertools/ramadan-and-diabetes</a></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [99]
                    </div>

                    <div class="column">
                      <p>Canadian Agency for Drugs and Technologies in Health. Low carbohydrate diet interventions for diabetes: Clinical effectiveness and guidelines. 2017 Apr. 13 pages.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [100]
                    </div>

                    <div class="column">
                      <p>Canadian Agency for Drugs and Technologies in Health. Intermittent fasting for adults with type 2 diabetes: A review of the clinical effectiveness and guidelines. 2019 Nov. 17 pages.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [101]
                    </div>

                    <div class="column">
                      <p>Radhakutty A, Burt MG. Management of endocrine disease: Critical review of the evidence underlying management of glucocorticoid-induced hyperglycaemia. European Journal of Endocrinology. 2018 Oct;179(4):R207–18.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [102]
                    </div>

                    <div class="column">
                      <p>Joint British Diabetes Societies for inpatient care. Management of hyperglycaemia and steroid (glucocorticoid) therapy. 2014 Oct. 28 pages.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [103]
                    </div>

                    <div class="column">
                      <p>Novo Nordisk Canada Inc. Product monograph: Awiqli® [Internet]. 2024. Available from: <a href="https://link.cep.health/t2dminhtml80" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">https://www.novonordisk.ca/content/dam/nncorp/ca/en/products/awiqli-en-product-monograph-12-march-2024.pdf</a></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [104]
                    </div>

                    <div class="column">
                      <p><span class="TextRun Highlight SCXW234746335 BCX8" lang="EN-CA" xml:lang="EN-CA" data-contrast="auto"><span class="NormalTextRun SCXW234746335 BCX8">Bajaj HS, Goldenberg RM. Insulin </span><span class="NormalTextRun SpellingErrorV2Themed SCXW234746335 BCX8">Icodec</span><span class="NormalTextRun SCXW234746335 BCX8"> Weekly: A Basal Insulin Analogue for Type 2 Diabetes. </span><span class="NormalTextRun SpellingErrorV2Themed SCXW234746335 BCX8">touchREV</span><span class="NormalTextRun SCXW234746335 BCX8"> Endocrinol. 2023 May;19(1):4-6.</span></span></p>
                    </div>
                  </li>

                            </ul>
           
</div>
</article>						</div>
					</div>
				</section>
							<section class="main-section" id="acknowledgement-and-legal" tabindex="-1">
					<div class="head">
						<div class="container">
							<h2 class="main-heading">
								Acknowledgement and legal								
    <span class="badge new" data-last-modified="Jun 23, 2023" data-hide-on-click>New</span>
							</h2>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
						</div>
					</div>
					<div class="body">
						<div class="container">
							<article class="block--legal-text ">
<div class="container">
  <div class="columns is-gapless">
    <div class="column is-8 text">
      <div class="inner">
        <p>The Type 2 diabetes: Insulin therapy tool (‘Tool’) was developed as part of the Knowledge Translation in Primary Care Initiative, led by the C<a href="https://cep.health/" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">entre for Effective Practice</a>, in collaboration with the and <a href="https://npao.org/" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Nurse Practitioners’ Association of Ontario</a>. Clinical leadership for the development of the Tool was provided by Dr. Risa Bordman and was subject to external review by health care providers and other relevant stakeholders. This Tool was funded by the Government of Ontario as part of the <a href="https://cep.health/case-studies/knowledge-translation-in-primary-care/" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Knowledge Translation in Primary Care Initiative</a>.</p>
<p>This Tool was developed for licensed health care professionals in Ontario as a guide only and does not constitute medical or other professional advice. Health care professionals are required to exercise their own clinical judgement in using this Tool. Neither the Centre for Effective Practice (“CEP”), Government of Ontario, Nurse Practitioners’ Association of Ontario, nor any of their respective agents, appointees, directors, officers, employees, contractors, members or volunteers: (i) are providing medical, diagnostic or treatment services through this Tool; (ii) to the extent permitted by applicable law, accept any responsibility for the use or misuse of this Tool by any individual including, but not limited to, primary care providers or entity, including for any loss, damage or injury (including death) arising from or in connection with the use of this Tool, in whole or in part; or (iii) give or make any representation, warranty or endorsement of any external sources referenced in this Tool (whether specifically named or not) that are owned or operated by their parties, including any information or advice contained therein.</p>
<p><em>This Tool is a product of the Centre for Effective Practice. Permission to use, copy, and distribute this material is for all noncommercial and research purposes is granted, provided the above disclaimer, this paragraph and the following paragraphs, and appropriate citations appear in all copies, modifications, and distributions. Use of this Tool for commercial purposes or any modifications of the Tool are subject to charge and must be negotiated with the Centre for Effective Practice (Email: <a href="mailto:info@cep.health">info@cep.health</a>).</em></p>
<p><img decoding="async" class="alignnone size-medium wp-image-327" src="https://tools.cep.health/wp-content/uploads/2019/10/CCLicense.svg" alt="" /></p>
<p>For statistical and bibliographic purposes, please notify the Centre for Effective Practice (<a href="mailto:info@cep.health">info@cep.health</a>) of any use or reprinting of the Tool. Please use the following citation when referencing the Tool: Reprinted with Permission from Centre for Effective Practice. (June 2023). Type 2 diabetes: Insulin therapy: Ontario. Toronto: Centre for Effective Practice.</p>
      </div>
    </div>
    <div class="column is-4 logos">
      <div class="inner">
                  <div>
            
                <p>
                  Developed by:                </p>

                
                  <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/CEP-Logo-Color.svg" />

                
            
                <p>
                  In collaboration with:                </p>

                
                  <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/NPAO-Logo.svg" />

                
                      </div>
              </div>
    </div>
  </div>
</div>
</article>						</div>
					</div>
				</section>
			
		</section>
  </main>

<div class="utility-bar">
    <button data-search-tool-open class="utility-button search-button"><i class="icon icon-search"></i></button>
    <a href="#top-of-sections" class="utility-button back-to-top"><i class="icon icon-arrow-up"></i></a>
</div>
<div class="global-modal"></div>

<script type="speculationrules">
{"prefetch":[{"source":"document","where":{"and":[{"href_matches":"\/*"},{"not":{"href_matches":["\/wp-*.php","\/wp-admin\/*","\/wp-content\/uploads\/*","\/wp-content\/*","\/wp-content\/plugins\/*","\/wp-content\/themes\/cep-tools\/*","\/*\\?(.+)"]}},{"not":{"selector_matches":"a[rel~=\"nofollow\"]"}},{"not":{"selector_matches":".no-prefetch, .no-prefetch a"}}]},"eagerness":"conservative"}]}
</script>
<!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: Obesity management HTML - enhance confidence -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'hhgajtyemrlknjsvrsd5');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: RSV HTML - change in patient care -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'tkia37pcyyahx6opqim2');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML Secure Messaging -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'ngtztpck7tvpbcvakl7d');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 AI LC - fill knowledge gaps -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'f2bzjhvjmeyfqkxxjggz');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML Social Rxing -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'qgchslypk4toxdtgsfsf');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML COPD -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'cfontzigzdapzyxtbhg4');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML Type 2 DM Insulin -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'nflzw9az1mcray2ltc4m');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML Type 2 DM Non-Insulin -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'edlo1w0s0lujgciyjgf9');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML ME/CFS -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'ybbyul2ujyofvsznkiti');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML FM -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'doewskxay35gb860nodl');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML Role Q -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'wm0xaeyycxvhthxjz76n');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML POTS -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'iqff27bs0pszfabitkgw');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML HF -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'xfup8pda84l5bd0udyje');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML A&D -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'xokl1h6esysgo5wdkq9d');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2022.11 E2P Patient Resource Page -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'jaxkt0icjnuu0z43iuik');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2021.11 MAID - Measuring knowledge -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'vso3vlstnsfjgeuogzry');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2021.11 Fall Prevention & MGMT Resource - Fill knowledge gaps -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'awihu5noxqqj5s7iasv8');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2021.08 PPIs - Change prescribing -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'cdikvvptidch9oj1o56k');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2021.08 Chronic Insomnia HTML - Increase Confidence -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'qeu7gqedkzjnotzskhln');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2021.08 Non-Medical Cannabis Resource - Fill knowledge gaps -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'okkbvdzprjjylm7wjkhe');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2021.07 ADHD Resource - Fill knowledge gaps -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'rxekv8i4pwnmp4zvclcm');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2020.05 COVID-19 - Change the way you will provide care for your patients? -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'koz3ranojk5yi8c5wmpe');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2020.07 CNCP - change in patient care -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'e6m4njfonyv93sqcttlx');</script>
<!-- / OptinMonster -->		<!-- Google Tag Manager (noscript) snippet added by Site Kit -->
		<noscript>
			<iframe src="https://www.googletagmanager.com/ns.html?id=GTM-WLFDZV" height="0" width="0" style="display:none;visibility:hidden"></iframe>
		</noscript>
		<!-- End Google Tag Manager (noscript) snippet added by Site Kit -->
				<script type="text/javascript">
		var hhgajtyemrlknjsvrsd5_shortcode = true;var tkia37pcyyahx6opqim2_shortcode = true;var ngtztpck7tvpbcvakl7d_shortcode = true;var f2bzjhvjmeyfqkxxjggz_shortcode = true;var qgchslypk4toxdtgsfsf_shortcode = true;var cfontzigzdapzyxtbhg4_shortcode = true;var nflzw9az1mcray2ltc4m_shortcode = true;var edlo1w0s0lujgciyjgf9_shortcode = true;var ybbyul2ujyofvsznkiti_shortcode = true;var doewskxay35gb860nodl_shortcode = true;var wm0xaeyycxvhthxjz76n_shortcode = true;var iqff27bs0pszfabitkgw_shortcode = true;var xfup8pda84l5bd0udyje_shortcode = true;var xokl1h6esysgo5wdkq9d_shortcode = true;var jaxkt0icjnuu0z43iuik_shortcode = true;var vso3vlstnsfjgeuogzry_shortcode = true;var awihu5noxqqj5s7iasv8_shortcode = true;var cdikvvptidch9oj1o56k_shortcode = true;var qeu7gqedkzjnotzskhln_shortcode = true;var okkbvdzprjjylm7wjkhe_shortcode = true;var rxekv8i4pwnmp4zvclcm_shortcode = true;var koz3ranojk5yi8c5wmpe_shortcode = true;var e6m4njfonyv93sqcttlx_shortcode = true;		</script>
		<style id='core-block-supports-inline-css' type='text/css'>
.wp-container-core-columns-is-layout-9d6595d7{flex-wrap:nowrap;}
</style>
<script>(function(d){var s=d.createElement("script");s.type="text/javascript";s.src="https://a.omappapi.com/app/js/api.min.js";s.async=true;s.id="omapi-script";d.getElementsByTagName("head")[0].appendChild(s);})(document);</script><script type="text/javascript" src="https://tools.cep.health/wp-content/themes/cep-tools/js/vendor.min.js" id="vendor-js"></script>
<script type="text/javascript" src="https://tools.cep.health/wp-content/themes/cep-tools/js/app.min.js?ver=1674670088" id="app-js"></script>
<script type="text/javascript" src="https://tools.cep.health/wp-content/plugins/glossary-by-codeat/assets/js/off-screen.js?ver=2.3.5" id="glossary-off-screen-js"></script>
<script type="text/javascript" src="https://tools.cep.health/wp-content/themes/cep-tools/assets/js/app/modules/slider.js?ver=6.4.2" id="block-acf-drug-options-js"></script>
<script type="text/javascript" src="https://tools.cep.health/wp-content/plugins/optinmonster/assets/dist/js/helper.min.js?ver=2.16.20" id="optinmonster-wp-helper-js"></script>
		<script type="text/javascript">var omapi_localized = {
			ajax: 'https://tools.cep.health/wp-admin/admin-ajax.php?optin-monster-ajax-route=1',
			nonce: '54d7109d0e',
			slugs:
			{"hhgajtyemrlknjsvrsd5":{"slug":"hhgajtyemrlknjsvrsd5","mailpoet":false},"tkia37pcyyahx6opqim2":{"slug":"tkia37pcyyahx6opqim2","mailpoet":false},"ngtztpck7tvpbcvakl7d":{"slug":"ngtztpck7tvpbcvakl7d","mailpoet":false},"f2bzjhvjmeyfqkxxjggz":{"slug":"f2bzjhvjmeyfqkxxjggz","mailpoet":false},"qgchslypk4toxdtgsfsf":{"slug":"qgchslypk4toxdtgsfsf","mailpoet":false},"cfontzigzdapzyxtbhg4":{"slug":"cfontzigzdapzyxtbhg4","mailpoet":false},"nflzw9az1mcray2ltc4m":{"slug":"nflzw9az1mcray2ltc4m","mailpoet":false},"edlo1w0s0lujgciyjgf9":{"slug":"edlo1w0s0lujgciyjgf9","mailpoet":false},"ybbyul2ujyofvsznkiti":{"slug":"ybbyul2ujyofvsznkiti","mailpoet":false},"doewskxay35gb860nodl":{"slug":"doewskxay35gb860nodl","mailpoet":false},"wm0xaeyycxvhthxjz76n":{"slug":"wm0xaeyycxvhthxjz76n","mailpoet":false},"iqff27bs0pszfabitkgw":{"slug":"iqff27bs0pszfabitkgw","mailpoet":false},"xfup8pda84l5bd0udyje":{"slug":"xfup8pda84l5bd0udyje","mailpoet":false},"xokl1h6esysgo5wdkq9d":{"slug":"xokl1h6esysgo5wdkq9d","mailpoet":false},"jaxkt0icjnuu0z43iuik":{"slug":"jaxkt0icjnuu0z43iuik","mailpoet":false},"vso3vlstnsfjgeuogzry":{"slug":"vso3vlstnsfjgeuogzry","mailpoet":false},"awihu5noxqqj5s7iasv8":{"slug":"awihu5noxqqj5s7iasv8","mailpoet":false},"cdikvvptidch9oj1o56k":{"slug":"cdikvvptidch9oj1o56k","mailpoet":false},"qeu7gqedkzjnotzskhln":{"slug":"qeu7gqedkzjnotzskhln","mailpoet":false},"okkbvdzprjjylm7wjkhe":{"slug":"okkbvdzprjjylm7wjkhe","mailpoet":false},"rxekv8i4pwnmp4zvclcm":{"slug":"rxekv8i4pwnmp4zvclcm","mailpoet":false},"koz3ranojk5yi8c5wmpe":{"slug":"koz3ranojk5yi8c5wmpe","mailpoet":false},"e6m4njfonyv93sqcttlx":{"slug":"e6m4njfonyv93sqcttlx","mailpoet":false}}		};</script>
				<script type="text/javascript">var omapi_data = {"object_id":27345,"object_key":"tools","object_type":"post","term_ids":[],"wp_json":"https:\/\/tools.cep.health\/wp-json","wc_active":false,"edd_active":false,"nonce":"9051981ff5"};</script>
		
  </body>
</html>
